Menu
Over the past 25 years, TROG Cancer Research has recorded 220 publications in national and international journals. View our current list of publications below.
| TROG Number | Acronym | Tumour | Citation | Category | Month/Year published | Journal |
|---|---|---|---|---|---|---|
| NA | - | NA | Lamb DS, Spry NA, Gray AJ, Johnson AD, Alexander SR, Dally MJ. Accelerated fractionation radiotherapy for advanced head and neck cancer. Radiother Oncol. 1990 Jun; 18(2):107-16. | NA | 1/06/1990 | Radiotherapy and Oncology |
| NA | - | NA | Gill PG, Denham JW, Jamieson GG, Devitt PH, Yeoh E, Olweny C. Patterns of treatment failure and prognostic factors associated with the treatment of esophageal carcinoma with chemotherapy and radiotherapy either as sole treatment or followed by surgery. J Clin Oncol. 1992 Jul; 10(7):1037-43. | NA | 1/07/1992 | Journal of Clinical Oncology |
| NA | - | NA | Hamilton CS, Denham JW, Joseph DJ, et al. Treatment and planning decisions in non-small cell carcinoma of the lung: an Australasian pattern of practice study. J Clin Oncol. 1992 May; 4(3):141-47. | NA | 1/05/1992 | Journal of Clinical Oncology |
| NA | - | NA | Hamilton CS and Denham JW. Dose normalisation and specification: from woe to go. Australas Radiol. 1992 May; 36(2):137-41. | NA | 1/05/1992 | Australasian Radiology |
| NA | - | NA | Denham JW, Hamilton CS, Joseph DJ, et al. The use of simulator and CT information in the planning of radiotherapy for non-small cell lung carcinoma; an Australasian pattern of practice study. Lung Cancer. 1993 Feb; 8(5-6):275-84. | NA | 1/02/1993 | Lung Cancer |
| NA | - | NA | Atkinson CH, Hamilton CS, Wynne CJ. Radiotherapy planning for lung cancer: Can we do better? Australas Radiol. 1994 Nov; 38(4):303-04. | NA | 1/11/1994 | Australasian Radiology |
| 89.04 | - | Gastrointestinal | Denham JW. Oesophageal cancer - guarded optimism. Med J Aust. 1994 Jun; 160(11):669-70. | A | 1/06/1994 | Medical Journal of Australia |
| 89.04 | - | Gastrointestinal | Burmeister BH, Denham JW, O'Brien M, Jamieson GG, Gill PG, Devitt P et al. Combined modality therapy for esophageal carcinoma: preliminary results from a large Australasian multicentre study. Int J Radiat Oncol Biol Phys. 1995 Jul; 32(4):997-1006. | A | 1/07/1995 | International Journal of Radiation Oncology Biology Physics |
| 89.02 | - | Breast | Denham JW, Hamilton CS, Christie D, O'Brien M, Bonaventura A, Stewart JF et al. Simultaneous adjuvant radiation therapy and chemotherapy in high-risk breast cancer - toxicity and dose modification: a Trans-Tasman Radiation Oncology Group multi-institution study. Int J Radiat Oncol Biol Phys. 1995 Jan; 31(2): 305-13. | A | 1/01/1995 | International Journal of Radiation Oncology Biology Physics |
| 89.02 | - | Breast | Christie DRH, O'Brien MY, Christie JA, Kron T, Ferguson SA, Hamilton CS et al. A comparison of methods of cosmetic assessment in breast conservation treatment. Breast. 1996 Oct; 5(5):358-67. | A | 1/10/1996 | Breast |
| 89.04 | - | Gastrointestinal | Denham JW, Burmeister BH, Lamb DS, Spry NA, Joseph DJ, Hamilton CS et al. Factors influencing outcome following radio-chemotherapy for oesophageal cancer. Radiother Oncol. 1996 Jul; 40(1):31-43. | A | 1/07/1996 | Radiotherapy and Oncology |
| 89.03 & 91.01 | - | Head and Neck/Gastrointestinal | Denham JW, Walker QJ, Lamb DS, Hamilton CS, O'Brien PC, Spry NA et al. Mucosal regeneration during radiotherapy. Trans Tasman Radiation Oncology Group (TROG). Radiother Oncol. 1996 Nov; 41(2):109-18. | A | 1/11/1996 | Radiotherapy and Oncology |
| 89.04 | - | Gastrointestinal | MacKean J, Burmeister BH, Lamb DS, Denham JW. Concurrent chemo-radiation for oesophageal cancer - Factors influencing myelotoxicity. Australas Radiol. 1996 Nov; 40(4):424-29. | A | 1/11/1996 | Australasian Radiology |
| 92.01 | - | Lymphoma | O'Brien PC, Roos D, Liew K-H, Trotter G, Barton M, Walker Q et al. Preliminary results of combined Chemotherapy and radiotherapy for non-AIDS primary Central Nervous System lymphoma. Trans-Tasman Radiation Oncology Group (TROG). Med J Aust. 1996 Oct; 165(8):424-27. | A | 1/10/1996 | Medical Journal of Australia |
| 89.04 | - | Gastrointestinal | Denham J and on behalf of the Trans-Tasman Radiation Oncology Group (TROG). Response to L. R. Coia re factors influencing outcome following radio-chemotherapy for oesophageal cancer. Radiother Oncol. 1997 Jan; 42(1): 91-2. (Letter) | A | 1/01/1997 | Radiotherapy and Oncology |
| 95.02 | - | Symptom Management | OBrien PC, Franklin CI, Dear KBG, Hamilton CS, et al. A phase III double-blind randomised study of rectal sucralfate suspension in the prevention of acute radiation proctitis: Trans-Tasman Radiation Oncology Group (TROG). Radiother Oncol. 1997 Nov; 45(2):11723. | A | 1/11/1997 | Radiotherapy and Oncology |
| 89.04 | - | Gastrointestinal | Smithers BM, Devitt P, Jamieson GG, Bessell J, Gotley D, Gill PG et al. A combined modality approach to the management of oesophageal cancer. Eur J Surg. 1997 Jun; 23(3):219-23. | A | 1/06/1997 | European Journal of Surgery |
| 89.04 | - | Gastrointestinal | Burmeister BH, Smithers BM, Denham JW. Combined modality therapy for carcinoma of the oesophagus: current status and future directions. Med J Aust. 1997 Oct; 167(7):349-50. | A | 1/11/1997 | Medical Journal of Australia |
| 89.03 | - | Gastrointestinal | Lamb DS, Denham JW, Morum PE, Gray AJ. Long-term results of accelerated radiation treatment for advanced head and neck cancer. A Trans-Tasman Radiation Oncology Group (TROG) Phase II study. Radiother Oncol. 1998 Oct; 49(1):29-32. | A | 1/10/1998 | Radiotherapy and Oncology |
| 91.01 | - | Head and Neck | Hamilton CS, Walker Q, Poulsen M, Spry N, Lamb D, Denham JW and Steigler A. Quality Assurance Audit in an Australasian Phase III Trial of Accelerated Radiotherapy for Head and Neck Cancer (TROG 91. 01). Australas Radiol. 1999 May; 43(2):227-32. | A | 1/05/1999 | Australasian Radiology |
| 91.01 | - | Head and Neck | Denham JW, Peters LJ, Johansen J, Poulsen M, Lamb DS, Hindley A, O'Brien P, Spry NA, Penniment M, Krawitz H, Williamson S, Bear J, Tripcony L. Do acute mucosal reactions lead to consequential late reactions in patients with head and neck cancer? Radiother Oncol. 1999 Aug; 52(2):157-64. | A | 1/05/1999 | Radiotherapy and Oncology |
| 89.02 | - | Breast | Lamb D, Atkinson C, Joseph D, O'Brien P, Ackland S, Bonaventura A, et al. Simultaneous adjuvant radiotherapy and chemotherapy for stage I and II breast cancer. Australas Radiol. 1999 May; 43(2):220-26. | A | 1/05/1999 | Australasian Radiology |
| 91.01 | - | Head and Neck | Poulsen M, Denham JW, Spry N, Lamb D, Peters L, Williamson S and L Tripcony. Acute toxicity and cost analysis of a phase III randomized trial of accelerated and conventional radiotherapy for squamous carcinoma of the head and neck: a Trans-Tasman Radiation Oncology Group study. Acute toxicity analysis of a phase III randomised trial of accelerated. Australas Radiol. 1999 Nov; 43(4):487-94. | A | 1/11/1999 | Australasian Radiology |
| 96.02 | - | Gastrointestinal | Denham JW, Ackland SP, Burmeister B, Walpole E, Lamb DS, Dady P and Spry N. Causes for increased myelosuppression with increasing age in patients with esophageal cancer treated by chemo-radiation. Eur J Cancer. 1999 Jun; 35(6):921-27. | A | 1/06/1999 | European Journal of Cancer |
| 96.01 | - | Genitourinary | Steigler A, Mameghan H, Lamb D, Joseph D, Matthews J, Franklin I, Turner S, Spry N, Poulsen M, North J, Kovacev O and Denham J. A quality assurance audit: Phase III trial of maximal androgen deprivation in prostate cancer (TROG 96. 01). Australas Radiol. 2000 Feb; 44(1): 65-71. | A | 1/02/2000 | Australasian Radiology |
| 96.05 | - | Symptom Management | Roos DE, Davis SR, O'Brien PC, Hoskin PJ, Spry NA, Burmeister BH, Turner S and Bernshaw D. Eligibility audits for the randomised neuropathic bone pain trial (Trans-Tasman Radiation Oncology Group Study, TROG 96. 05). Australas Radiol. 2000 Aug; 44(3):303-07. | A | 1/08/2000 | Australasian Radiology |
| 96.05 | - | Symptom Management | Roos DE, O'Brien PC, Smith JG, Spry NA, Hoskin PJ, Burmeister BH, Turner S and Bernshaw D. A role for radiotherapy in neuropathic bone pain: preliminary response rates from a prospective trial (Trans-Tasman Radiation Oncology Group, TROG 96. 05). Int J Radiat Oncol Biol Phys. 2000 Mar; 46(4): 975-81. | A | 1/03/2000 | International Journal of Radiation Oncology Biology Physics |
| 92.01 | - | Lymphoma | O'Brien P, Roos D, Pratt G, Liew K, Barton M, Poulsen M, Olver I and Trotter G. Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma. J Clin Oncol. 2000 Feb; 18(3):519-26. | A | 1/02/2000 | Journal of Clinical Oncology |
| 91.01 | - | Head and Neck | Poulsen M, Denham J, Peters L, Lamb D, Spry NA, Hindley A, Krawitz, H Hamilton C, Keller J, Tripcony L, Walker Q. A randomised trial of accelerated and conventional radiotherapy for stage III and IV squamous carcinoma of the head and neck: A Trans-Tasman Radiation Oncology Group Study (TROG 91.01). Radiother Oncol. 2001 Aug; 60(2):113-22. | A | 1/08/2001 | Radiotherapy and Oncology |
| 98.01 | - | Gastrointestinal | Ngan SYK, Burmeister BH, Fisher R, Rischin D, Schache DJ, Kneebone A, MacKay JR, Joseph D, Bell A and Goldstein D. Early toxicity from preoperative radiotherapy with continuous infusion 5-fluorouracil for resectable adenocarcinoma of rectum. A phase II trial for the Trans-Tasman Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2001 Jul; 50(4):883-87. | A | 1/07/2001 | International Journal of Radiation Oncology Biology Physics |
| 96.07 | - | Skin | Poulsen M, Rischin D, Walpole E, Harvey J, Macintosh J, Ainslie J, Hamilton C, Keller J Tripcony L. Analysis of toxicity of Merkel Cell Carcinoma of the skin treated with synchronous carboplatin/etopside and radiation: A Trans-Tasman Radiation Oncology Group study - TROG 96. 07. Int J Radiat Oncol Biol Phys. 2001 Sep; 51(1):156-63. | A | 1/09/2011 | International Journal of Radiation Oncology Biology Physics |
| 91.01 | - | Head and Neck | Denham JW and Kron T. Extinction of the weakest. Int J Radiat Oncol Biol Phys. 2001 Nov; 51(3): 80719. | A | 1/11/2001 | International Journal of Radiation Oncology Biology Physics |
| 96.06 | - | Skin | Burmeister BH, Smithers BM, Davis S, Spry N, Johnson C Krawitz H, Baumann KC. Radiation therapy following nodal surgery for melanoma: An analysis of toxicity. ANZ J Surg. 2002 May; 72(5):34448. | A | 1/05/2002 | ANZ Journal of Surgery |
| 96.01 & 91.01 | - | Genitourinary/Head and Neck | Kron T, Hamilton C, Roff M, Denham JW. Dosimetric intercomparison for two Australasian clinical trials using an anthropomorphic phantom. Int J Radiat Oncol Biol Phys. 2002 Feb; 52(2):56679. | A | 1/02/2002 | International Journal of Radiation Oncology Biology Physics |
| 95.02 | - | Symptom Management | O'Brien PC, Franklin CI, Joseph DJ, Spry NS, Denham JW. Acute symptoms, not rectally administered Sucralfate, predict for late radiation proctitis. Longer-term follow-up of a Phase 3 trial Trans-Tasman Radiation Oncology Group (TROG). Int J Radiat Oncol Biol Phys. 2002 Oct; 54(2):44249. | A | 1/02/2002 | International Journal of Radiation Oncology Biology Physics |
| 96.02 + 89.04 | - | Gastrointestinal | Denham JW, Steigler A, Kilmurray J, Wratten C, Burmeister B, Lamb DS, Joseph D Delaney G, Christie D, Jamieson G, Smithers BM, Ackland S, Walpole E. Relapse patterns after chemo-radiation for carcinoma of the oesophagus. J Clin Oncol. 2003 May; 15(3): 98108. | A | 1/05/2003 | Journal of Clinical Oncology |
| 96.05 | - | Symptom Management | Roos DE, Davis SR, Turner SL, OBrien PC, Spry NA, Burmeister BH, Hoskin PJ and Ball DL. Quality assurance experience with the randomised neuropathic bone pain trial (Trans-Tasman Radiation Oncology Group, 96.05). Radiother Oncol. 2003 May; 67(2):20712. | A | 1/05/2003 | Radiotherapy and Oncology |
| 91.01 | - | Head and Neck | Daly T, Poulsen GM, Denham JW, Peters LJ, Lamb DS, Krawitz H, Hamilton C, Keller J, Tripcony L, Walker Q. The effect of anaemia on efficacy and normal tissue toxicity following radiotherapy for locally advanced squamous cell carcinoma of the head and neck. Radiother Oncol. 2003 Aug; 68(2): 11322. | A | 1/08/2003 | Radiotherapy and Oncology |
| 96.01 | - | Genitourinary | Lamb DS, Denham JW, Mameghan H, Joseph D, Turner S, Matthews J, Franklin I, Atkinson C, North J, Poulsen M, Kovacev O, Robertson R, Francis L, Christie D, Spry NA, Tai KH, Wynne C, Duchesne G. Acceptability of short term neo-adjuvant androgen deprivation in patients with locally advanced prostate cancer. Radiother Oncol. 2003 Sep; 68(3):25567. | A | 1/09/2003 | Radiotherapy and Oncology |
| 98.04 | - | Symptom Management | Bydder S, Spry NA, Christie DRH, Roos D, Burmeister BH, Krawitz H, Davis S, Joseph DJ, Poulsen M, Berry M. A prospective trial of short-fractionation radiotherapy for the palliation of liver metastases. Australas Radiol. 2003 Sep; 47(3):28488. | A | 1/09/2003 | Australasian Radiology |
| 96.07 | - | Skin | Poulsen M, Rischin D, Walpole E, Harvey J, Mackintosh J, Ainslie J, Hamilton C, Keller J, Tripcony L. High-Risk Merkel Cell Carcinoma of the Skin Treated With Synchronous Carboplatin/Etoposide and Radiation: A Trans-Tasman Radiation Oncology Group StudyTROG 96:07. J Clin Oncol. 2003 Dec; 21(23): 4371-76. | A | 1/12/2003 | Journal of Clinical Oncology |
| - | - | NA | Christie D, Sharpley C, Curtis T. Improving the Accuracy of a Photographic Assessment System for Breast Cosmesis. J Clin Oncol. 2005 Feb; 17(1):27-31. | NA | 1/02/2005 | Journal of Clinical Oncology |
| 96.05 | - | Symptom Management | Roos D, Turner S, O'Brien P, Smith J, Spry N, Burmeister B, Hoskin P, Ball D. Randomized trial of 8Gy in 1 versus 20Gy in 5 fractions of radiotherapy for neuropathic pain due to bone metastases (Trans-Tasman Radiation Oncology Group, TROG 96.05). Radiother Oncol. 2005 Apr; 75(1):54-63. | A | 1/04/2005 | Radiotherapy and Oncology |
| 98.02 | - | Head and Neck | Rischin D, Peters L, Fisher R, Macann A, Denham J, Poulsen M, Jackson M, Kenny L, Penniment M, Corry J, Lamb D, McClure B. Tirapazamine, Cisplatin, and Radiation Versus Fluorouracil, Cisplatin, and Radiation in Patients With Locally Advanced Head and Neck Cancer: A Randomized Phase II Trial of the Trans Tasman Radiation Oncology Group (TROG 98.02). J Clin Oncol. 2005 Jan; 23(1):79-87. | A | 1/01/2005 | Journal of Clinical Oncology |
| 94.01 | - | Gastrointestinal | Burmeister BH, Smithers BM, Gebski V, Fitzgerald L, Simes RJ, Devitt P, Ackland S, Gotley DC, Joseph D, Millar J, North J, Walpole ET, Denham JW. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol. 2005 Sep; 6(9):659-68. | A | 1/09/2005 | Lancet Oncology |
| 96.05 | - | Symptom Management | Pollicino CA, Turner SL, Roos DE, OBrien PC. Costing the components of pain management. Analysis of Trans-Tasman Radiation Oncology Group trial (TROG 96.05): One versus five fractions for neuropathic bone pain. Radiother Oncol. 2005 Sep; 76(3):26469. | A | 1/03/2005 | Radiotherapy and Oncology |
| 96.01 | - | Genitourinary | Christie D, Denham J, Steigler A, Lamb D, Turner S, Mameghan H, Joseph D, Matthews J, Franklin I, Atkinson C, North J, Poulsen M, Spry N, Tai K, Wynne C, Duchesne G, Kovacev O, Francis L, Kramar A, DEste C, Bill D. Delayed rectal and urinary symptomatology in patients treated for prostate cancer by radiotherapy with or without short term neo-adjuvant androgen deprivation. Radiother Oncol. 2005 Nov; 77(2):117-25. | A | 1/11/2005 | Radiotherapy and Oncology |
| 96.01 | - | Genitourinary | Denham JW, Steigler A, Lamb DS, Joseph D, Mameghan H, Turner S, Matthews J, Franklin I, Atkinson C, North J, Poulsen M, Christie D, Spry NA, Tai K-H, Wynne C, Duchesne G, Kovacev O, DEste C. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol. 2005; 6(11):841-50 | A | xx/xx/2005 | Lancet Oncology |
| 98.01 | - | Gastrointestinal | Ngan SYK, Fisher R, Burmeister BH, Mackay J, Goldstein D, Kneebone A, Schache D, Joseph D, McKendrick J, Leong T, McClure B, Rischin D. Promising results of a co-operative group phase II trials of preoperative chemoradiation for locally advanced rectal cancer (TROG 9801). Dis Colon Rectum. 2005 Jul; 48(7):1389-96. | A | 1/07/2005 | Diseases of the Colon and Rectum |
| 3.06 | TOAD | Genitourinary | Duchesne, GM, Syme R, Howell D. How early is early: Androgen deprivation for prostate-specific antigen relapse in prostate cancer. J Clin Oncol. 2006 June; 24(18):2964-64. | A | 1/06/2006 | Journal of Clinical Oncology |
| 1.05 | - | Symptom Management | Graham PH, Capp A, Delaney G, Goozee G, Hickey B, Turner S, Browne L, Milross C, Wirth A. A pilot randomised comparison of Dexamethasone 96 mg versus 16mg per day for malignant spinal-cord compression treated by radiotherapy: TROG 01.05 Superdex Study. J Clin Oncol. 2006 Feb; 18(1):70-6. | A | 1/02/2006 | Journal of Clinical Oncology |
| 96.07 | - | Skin | Poulsen M, Rischin D, Porter I, Walpole E, Harvey J, Hamilton C, Keller J, Tripcony L. Does Chemotherapy improve survival in high risk stage I and II Merkel Cell Carcinoma of the skin? Int J Radiat Oncol Biol Phys. 2006 Jan; 64(1):114-19. | A | 1/01/2006 | International Journal of Radiation Oncology Biology Physics |
| 92.01 | - | Lymphoma | OBrien PC, Roos DE, Pratt G, Liew K-H, Barton MB, Poulsen MG, Olver IA, Trotter GE. Combined-modality Therapy for Primary Central Nervous System Lymphoma: Long-term Data from a Phase II Multi-center Study (Trans-Tasman Radiation Oncology Group). Int J Radiat Oncol Biol Phys. 2006 Feb; 64(2):408-13. | A | 1/02/2006 | International Journal of Radiation Oncology Biology Physics |
| 3.08 | - | Symptom Management | Chow E, Hoskin P, Wu J, Roos D, van der Linden Y, Hartsell W, Vieth R, Wilson C, Pater J. A Phase III International Randomised Trial Comparing Single with Multiple Fractions for Re-irradiation of Painful Bone Metastases: National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) SC 20. J Clin Oncol. 2006 Mar; 18 (2):125-128. (Editorial) | B | 1/03/2006 | Journal of Clinical Oncology |
| - | - | NA | Chen Y, Trotti A, Coleman CN, Machtay M, Mirimanoff RO, Hay J, OBrien PC, El-Gueddari B, Salvajoli JV, Jeremic B. Adverse Event Reporting And Developments In Radiation Biology After Normal Tissue Injury: International Atomic Energy Agency Consultation. Int J Radiat Oncol Biol Phys. 2006 Apr; 64(5):144251. | NA | 1/04/2006 | International Journal of Radiation Oncology Biology Physics |
| 98.02 | - | Head and Neck | Rischin D, Hicks RJ, Fisher R, Binns D, Corry J, Porceddu S and Peters LJ. Prognostic significance of [F-18]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: A substudy of Trans-Tasman Radiation Oncology Group study 98.02. J Clin Oncol. 2006 May; 24(13):2098-04. | A | 1/05/2006 | Journal of Clinical Oncology |
| 99.05 | - | Lung | Ball DL, Fisher R, Burmeister B, Graham P, Joseph D, Penniment M, Krawitz H, Wheeler G, Poulsen M, Vinod S and McClure B. Stage is not a reliable indicator of tumor volume in non-small cell lung cancer: a preliminary analysis of the Trans-Tasman Radiation Oncology Group 99-05 database. J Thorac Oncol. 2006 Sep; 1(7):667-72. | A | 1/09/2006 | Journal of Thoracic Oncology |
| 98.05 | - | Central Nervous System | Roos D, Wirth A, Burmeister B, Spry N, Drummond K, Beresford J and McClure B. Whole brain irradiation following surgery or radiosurgery for solitary brain metastases: Mature results of a prematurely closed randomized Trans-Tasman Radiation Oncology Group trial (TROG 98.05). Radiother Oncol. 2006 Sep; 80(3):318-22. | A | 1/09/2006 | Radiotherapy and Oncology |
| 99.06 + 97.01 | - | Genitourinary/Gastrointestinal | Gogna N, Matthews J, Turner S, Mameghan H, Duchesne G, Spry N, Berry M, Keller J and Tripcony L. Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: A report of two sequential Phase II studies from the Trans Tasman Radiation Oncology Group. Radiother Oncol. 2006 Oct; 81(1):917. | A | 1/10/2006 | Radiotherapy and Oncology |
| 96.06 | - | Skin | Burmeister B. Smithers M, Burmeister E, Baumann K, Davis S, Krawitz H, Johnson C and Spry N. A prospective phase II study of adjuvant postoperative radiation therapy following nodal surgery in malignant melanoma - Trans Tasman Radiation Oncology Group (TROG) study 96.06. Radiother Oncol. 2006 Nov; 81(2):13642. | A | 1/11/2006 | Radiotherapy and Oncology |
| 99.04 | - | Lymphoma | Christie DR, Gabriel GS and Dear K. Adverse effects of a multicentre system for ethics approval on the progress of a prospective multicentre trial of cancer treatment: how many patients die waiting? Intern Med J. 2007 Oct; 37(10):680-86. | A | 1/10/2007 | Internal Medicine Journal |
| 96.01 | - | Genitourinary | DAmico A, Denham J, Crook J, Chen M-H, Goldhaber S, Lamb D, Joseph D, Keen-Hun T, Malone S, Ludgate C, Steigler A, Kantoff P. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol. 2007 Jun; 25(17):2420-25. | A | 1/06/2007 | Journal of Clinical Oncology |
| 96.01 | - | Genitourinary | DAmico A, Denham J, Bolla M, Collette L, Lamb D, Thai K-H, Steigler A, Chen M-H. Short versus long-term androgen suppression plus external beam radiation therapy and survival in men of advanced age with node negative high-risk adenocarcinoma of the prostate. Cancer. 2007 May; 109(10):2004-10. | A | 1/05/2007 | Cancer |
| 98.02 | - | Head and Neck | Corry J, Peters L, Fisher R, Macann A, Jackson M, McClure B, Rischin D. N2-N3 neck nodal control without planned neck dissection for clinical/radiologic complete responders - Results of Trans Tasman Radiation Oncology Group study 98.02. Head Neck. 2008 Jun; 30(6):737-42. | A | 1/06/2008 | Head and Neck (OtolaryngologyHead and Neck Surgery) |
| 96.01 | - | Genitourinary | Denham JW, Steigler A, Wilcox C, Lamb D, Joseph D, Atkinson C, Matthews J, Tai K, Spry N, Christie D, Gleeson P, Greer PB, D'Este C, on behalf of the Trans-Tasman Radiation Oncology Group 96.01 Trialists. Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial. Lancet Oncol. 2008 Nov; 9(11):105868. | A | 1/11/2008 | Lancet Oncology |
| 3.04 | RADAR | Genitourinary | Ebert MA, Howlett SJ, Harrison K, Cornes D, Hamilton CS, Denham JD. Linear-accelerator X-ray output: a multicentre chamber-based intercomparison study in Australia and New Zealand. Australas Phys Eng Sci Med. 2008 Dec; 31(4):255-66. | A | 1/12/2008 | Australasian Radiology |
| 3.04 | RADAR | Genitourinary | Haworth A, Kearvell R, Greer PB, Hooton B, Denham JW, Lamb D, Duchesne G, Murray J, Joseph D. Assuring high quality treatment delivery in clinical trials Results from the Trans-Tasman Radiation Oncology Group (TROG) study 03.04 RADAR set-up accuracy study. Radiother Oncol. 2009 Mar; 90(3):299-306. | A | 1/03/2009 | Radiotherapy and Oncology |
| 6.02 | APBI | Breast | Kron T, Willis D, Miller J, Hubbard P, Oliver M, Chua B. A spreadsheet to determine the volume ratio for target and breast in partial breast irradiation. Australas Phys Eng Sci Med. 2009 Jun; 32(2):98-104. | A | 1/06/2009 | Australasian Physical and Enginerring Sciences in Medicine |
| 96.01 | - | Genitourinary | Capp A, Inostroza-Ponta M, Bill D, Moscato P, Lai C, Christie D, Lamb D, Turner S, Joseph D, Matthews J, Atkinson C, North J, Poulsen M, Spry N, Tai KH, ; Wynne C, Duchesne G, Steigler A, Denham JW. Is there more than one proctitis syndrome? A revisitation using data from the TROG 96.01 trial. Radiother Oncol. 2009 Mar; 90(3):400-07. | A | 1/03/2009 | Radiotherapy and Oncology |
| 96.01 | - | Genitourinary | Denham JW, Lamb DS, Joseph D, Matthews J, Atkinson C, Spry, NA, Duchesne G, Ebert M, Steigler A, D'Este C. PSA response signatures - a powerful new prognostic indicator after radiation for prostate cancer? Radiother Oncol. 2009 Mar; 90(3):382-88. | A | 1/03/2009 | Radiotherapy and Oncology |
| 96.01 | - | Genitourinary | Denham JW, Kumar M, Gleeson PS, , Lamb DS; Joseph D; Atkinson C, Matthews J, Tai KH, Spry NA, Christie D, Turner S, Greer PB, D'Este C, Steigler A. Recognising false biochemical failure calls after radiation with or without neo-adjuvant androgen deprivation for prostate cancer. Int J Radiat Oncol Biol Phys. 2009 Jun; 74(2):404-11. | A | 1/06/2009 | International Journal of Radiation Oncology Biology Physics |
| 99.04 | - | Lymphoma | Christie D, Le T, Watling K, Cornes D, OBrien P, Hitchins R. Quality assurance audit: A prospective non-randomised trial of chemotherapy and radiotherapy for osteolymphoma (TROG 99.04/ALLG LY02). J Med Imag Radiat Oncol. 2009 Apr; 53(2):20306. | A | 1/04/2009 | Journal Of Medical Imaging And Radiation Oncology |
| 6.02 | APBI | Breast | Kron T, Willis D, Bignell F, Martland J, Donnell S, May S, Chua BH. Centre credentialing for Trans Tasman Radiation Oncology Group trial 06.02: multicentre feasibility study of accelerated partial breast irradiation. J Med Imag Radiat Oncol. 2009 Aug; 53(4):41218. | A | 1/08/2009 | Journal Of Medical Imaging And Radiation Oncology |
| 96.01 | - | Genitourinary | Denham JW, Steigler A, Kumar M, Lamb DS, Spry NA, Tai K, Atkinson C, Turner S, Greer PG, Gleeson PS, DEste C. Measuring time to Biochemical Failure in the TROG 96.01 Trial: When should the clock start ticking? Int J Radiat Oncol Biol Phys. 2009 Nov; 75 (4):1008-12. | A | 1/11/2009 | International Journal of Radiation Oncology Biology Physics |
| 3.04 | RADAR | Genitourinary | Ebert MA, Harrison K, Cornes D, Howlett SJ, Joseph DJ, Kron T, Hamilton CS, Denham JW. Comprehensive Australasian multicentre dosimetric intercomparison: Issues, logistics and recommendations. J Med Imag Radiat Oncol. 2009 Feb; 53(1):119-13. | A | 1/02/2009 | Journal Of Medical Imaging And Radiation Oncology |
| 96.01 | - | Genitourinary | Denham JW, Steigler A, Wilcox C, Lamb DS, Joseph D, Atkinson C, Tai K-H, Spry NA, Gleeson PS, DEste C. Why are pretreatment PSA levels and biochemical recurrence poor predictors of prostate cancer survival? Cancer. 2009 Oct; 115(19):4477-87. | A | 1/10/2009 | Cancer |
| 3.04 | RADAR | Genitourinary | Galvao DA, Spry N, Taaffe DR, Denham J; Joseph D; Lamb DS; Levin G ; Duchesne, G, Newton RU.A randomized controlled trial of an exercise intervention targeting cardiovascular and metabolic risk factors for prostate cancer patients from the RADAR trial. BMC Cancer. 2009 Dec; 9: 419. | A | 1/12/2009 | BMC Cancer |
| 2.02 | - | Head and Neck | Rischin D, Peters LJ, O'Sullivan B, Giralt J, Fisher R, Yuen K, Trotti A, Bernier J, Bourhis J, Ringash J, Henke M, Kenny L. Tirapazamine, Cisplatin, and Radiation Versus Cisplatin and Radiation for Advanced Squamous Cell Carcinoma of the Head and Neck (TROG 02.02, HeadSTART): A Phase III Trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol. 2010 Jun; 28(18):2989-95. | A | 1/06/2010 | Journal of Clinical Oncology |
| 2.02 | - | Head and Neck | Peters LJ, O'Sullivan B, Giralt J, Fitzgerald TJ, Trotti A, Bernier J, Bourhis J, Yuen K, Fisher R, Rischin D. Critical Impact of Radiotherapy Protocol Compliance and Quality in the Treatment of Advanced Head and Neck Cancer: Results From TROG 02.02. J Clin Oncol. 2010 Jun; 28(18):2996-3001. | A | 1/06/2010 | Journal of Clinical Oncology |
| 9.02 | CHISEL | Lung | Clements N, Kron T, Dunn L, Aarons Y, Cheeson B, Miller J, Ball D. Patient-specific QA for motion management in hypofractionated lung radiotherapy. Med Phys. 2010; 37: 3420. | A | xx/xx/2010 | Medical Physics |
| 96.01 | - | Genitourinary | Kumar M, Steigler A and Denham JW. The value of combined androgen blockade in the neo-adjuvant treatment of localised prostate cancer the jury must remain out. (Letter to the Editor) J Clin Oncol. 2010 Sep; 28(25):e445-46. | A | 09/201 | Journal of Clinical Oncology |
| 3.04 | RADAR | Genitourinary | Delahunt B, Lamb DS, Srigley JR, et al. Gleason scoring: a comparison of classical and modified (International Society of Urological Pathology) criteria using nadir PSA as a clinical end point. Pathology. 2010 Jun; 42(4):339-43. | A | 1/06/2010 | Pathology |
| 2.02 | - | Head and Neck | Rischin D, Young RJ, Fisher R, Fox SB, Le QT, Peters LJ, Solomon B, Choi J, OSullivan B, Kenny LM, McArthur GA. Prognostic Significance of p16INK4A and Human Papillomavirus in patients with Oropharyngeal Cancer Treated on TROG 02.02 Phase III trial. J Clin Oncol. 2010 Sep; 28(27):4142-48. | A | 1/09/2010 | Journal of Clinical Oncology |
| 3.08 | - | Symptom Management | Roos D. Response to Determining the incidence of pain flare following palliative radiotherapy for symptomatic bone metastases: Results from three Canadian centers. Int J Rad Onc Biol Phys. 2010 Oct; 78(2):637. | B | 1/10/2010 | International Journal of Radiation Oncology Biology Physics |
| 3.06 | TOAD | Genitourinary | Duchesne GM, Woo HH, Howell D, Kaimakamis M, Kemp E. Tribulations of a prostate cancer trial lessons learned from TOAD, a Cancer Council Victoria and Transtasman Radiation Oncology Group trial. J Med Imag Radiat Oncol. 2010 Oct; 54(5):508-11. | A | 1/10/2010 | Journal Of Medical Imaging And Radiation Oncology |
| 3.04 | RADAR | Genitourinary | Ebert MA, Haworth A, Kearvell R, Hooton B, Hug B, Spry NA, Bydder SA, Joseph DJ. Comparison of DVH data from multiple radiotherapy treatment planning systems. Phys Med Biol. 2010 Jun; 55(11):N337-46. | A | 1/06/2010 | Physics in Medicine and Biology |
| 96.01 | - | Genitourinary | Lamb DS, Denham JW, Joseph D, Matthews J, Atkinson C, Spry NA, Duchesne G, Ebert M, Steigler A, Delahunt B, DEste C. A comparison of the prognostic value of early PSA based variables following external beam radiotherapy, with or without preceding androgen deprivation: analysis of data from the TROG 96.01 randomized trial. Int J Radiat Oncol Biol Phys. 2011 Feb; 79(2);385-391. | A | 1/02/2011 | International Journal of Radiation Oncology Biology Physics |
| 99.04 | - | Lymphoma | Christie D, Dear K, Le T, Barton M, Wirth A, Porter D, Roos D, Pratt G. Limited Chemotherapy and Shrinking Field radiotherapy for Osteolymphoma (primary bone lymphoma): Results from the Trans Tasman radiation Oncology Group 99.04 and Australasian Leukemia and Lymphoma Group LY02 Prospective Trial. Int J Radiat Oncol Biol Phys. 2011 Jul; 80(4):1164-70. | A | 1/07/2011 | International Journal of Radiation Oncology Biology Physics |
| 8.01 | PROFIT | Genitourinary | Middleton M, Frantzis J, Healy B, Jones M, Murry R, Kron T, Plank A, Catton C, Martin J. Successful Implementation of Image Guided radiation therapy Quality Assurance in the Trans Tasman Radiation Oncology Group 08.01 PROFIT Study. Int J Rad Onc Biol Phys. 2011 Dec; 81(5):1576-81. | B | 1/12/2011 | International Journal of Radiation Oncology Biology Physics |
| 99.02 | - | Gastrointestinal | Matthews J, Burmeister B, Borg M, Capp A, Joseph D, Thompson KM, Thompson PI, Harvey JA, Spry NA. T1-2 anal carcinoma requires elective inguinal radiation treatment- the results of Trans Tasman Radiation Oncology Group study TROG 99.02. Radiother Oncol. 2011 Jan; 98(1):93-98. | A | 1/01/2011 | Radiotherapy and Oncology |
| 3.02 | - | Gastrointestinal | Leong T, Lim Joon D, Willis D, Jayamoham J, Spry N, Harvey J, Di lulio J, Milner A, Mann GB, Michael M. Adjuvant chemoradiation for gastric cancer using epirubicin, Cisplatin, and 5-fluorouracil before and after three-dimensional Conformal radiotherapy with concurrent infusional 5-fluorouracil: a multicenter study of the trans-tasman radiation Oncology group. Int J Radiat Oncol Biol Phys. 2011 Mar; 79(3):690-95. | A | 1/03/2011 | International Journal of Radiation Oncology Biology Physics |
| 99.01 | - | Lymphoma | Wirth A, Grigg A, Wolf M, Goldstein D, Johnson C, Davis S, Dutu G, Kypreos P, Smith C, Kneebone A, Herzberg M, Joseph D, Catalano J, Roos D, Reynolds J. Risk and Response Adapted Therapy for Early Stage Hodgkin Lymphoma: A Prospective Multi-Centre Study of the Australasian Leukaemia and Lymphoma Group/Trans-Tasman Radiation Oncology Group. Leuk Lymphoma. 2011; 52(5):78695. | A | xx/xx/2011 | Leukemia and Lymphoma |
| 9.02 | CHISEL | Lung | Kron T, Clements N, Aarons Y, Dunn L, Cheeson B, Miller J, Roozen K, Ball D. Radiochromic film for individual patient QA in extracranial stereotacic lung radiotherapy. Radiat Meas. 2011; 46:1920-23. | A | xx/xx/2011 | Radiation Measurements |
| 8.01 | PROFIT | Genitourinary | Healy B, Frantzis J, Murry R, Martin J, Middleton M, Catton C, Kron T. Development of a dosimetry inter-comparison for IMRT as part of site credentialing for a TROG multi-centre clinical trial for prostate cancer. Australas Phys Eng Sci Med. 2011 Jun; 34(2):195-202. | B | 1/06/2011 | Australasian Physical and Enginerring Sciences in Medicine |
| 3.07 | - | Lung | Burmeister BH, Michael M, Burmeister E, Cox S, Lehman M, Wirth A, Horwood K, Sasso G, Forouzesh B, Ball D. A randomised phase II trial of 2 regimens of moderate dose chemoradiation therapy for patients with non small cell lung cancer not suitable for curative therapy - Trans Tasman Radiation Oncology Study TROG 03.07. J Thorac Oncol. 2011 Dec; 6(12):2076-82. | A | 1/12/2011 | Journal of Thoracic Oncology |
| 96.01 | - | Genitourinary | Denham JW, Steigler A, Lamb DS, Joseph D, Turner S, Matthews J, Atkinson C, North J, Christie C, Spry NA, Tai K-H, Wynne C, DEste C. Short term neoadjuvant androgendeprivation and radiotherapy for locally advanced prostate cancer: 10 year data from the TROG 96.01 randomised trial. Lancet Oncol. 2011 May; 12(5):451-59. | A | 1/05/2011 | Lancet Oncology |
| 8.03 | RAVES | Genitourinary | Sundaresan P, Turner S, Kneebone A, Pearse M, Butow P. Evaluating the utility of a patient decision aid for potential participants of a prostate cancer trial (RAVES-TROG 08.03). Radiother Oncol. 2011 Dec; 101(3):521-524. | A | 1/12/2011 | Radiotherapy and Oncology |
| 96.01 | - | Genitourinary | DAmico AV, Chen M-H, Crook J, Armstrong JG, Malone S, Steigler A, Dunne M, Kantoff PW, and Denham JW. Duration of short course androgen suppression therapy and the risk of death from prostate cancer. J Clin Oncol. 2011 Dec; 29(35):4682-87. | A | 1/12/2011 | Journal of Clinical Oncology |
| 96.01 | - | Genitourinary | Denham JW, Lamb DS, Joseph D, Matthews J, Atkinson C, Spry NA, Duchesne G, Ebert M, Steigler A and DEste C. Another form of subgroup to beware. (Letter to the Editor). Radiother Oncol. 2011 Dec; 101(3): 525-526. | A | 1/12/2011 | Radiotherapy and Oncology |
| 3.04 | RADAR | Genitourinary | Harrison KM, Ebert MA, Kron T, Howlett SJ, Cornes D, Hamilton CS, Denham JW. Design, manufacture and evaluation of an anthropomorphic pelvic phantom purpose-built for radiotherapy dosimetric intercomparison. Med Phys. 2011 Oct; 38(10):5330-37. | A | 1/10/2011 | Medical Physics |
| 3.04 | RADAR | Genitourinary | Ebert MA, Harrison KM, Howlett SJ, Cornes D, Bulsara M, Hamilton CS, Kron T, Joseph DJ, Denham JW. Dosimetric intercomparison for multicenter clinical trials using a patient-based anatomic pelvic phantom. Med Phys. 2011 Sep; 38(9):5167-75. | A | 1/09/2011 | Medical Physics |
| 2.02 | - | Head and Neck | Young R, Rischin D; Fisher R; et al. Relationship between Epidermal Growth Factor Receptor Status, p16(INK4A), and Outcome in Head and Neck Squamous Cell Carcinoma. Cancer Epidemiol Biomar Prev. 2011 Jun; 20(6):1230-37. | A | 1/06/2011 | Cancer Epidemiology Biomarkers and Prevention |
| 2.02 | - | Head and Neck | Lim AM, Rischin D, Fisher R, Cao H, Kwok K, Truong D, McArthur GA, Young RJ, Giaccia A, Peters L, Le QT. Prognostic significance of Plasma Osteopontin in patients with locoregionally advanced head and neck squamous cell carcinoma treated on TROG 02.02 Phase III Trial. Clin Cancer Res. 2012 Jan; 18(1):301-07. | A | 1/01/2012 | Clinical Cancer Research |
| 96.01 | - | Genitourinary | DAmico AV, Chen M-H, de Castro M, Loffredo M, Lamb DS, Steigler A, Kantoff PW and Denham JW. Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials. Lancet Oncol. 2012 Feb; 13 (2) 189-95. | A | 1/02/2012 | Lancet Oncology |
| TROG | - | NA | Grand M, OBrien P. Obstacles to participation in randomised cancer clinical trials: a systematic review of the literature. J Med Imag Radiat Oncol. 2012 Feb; 56(1):31-9. | NA | 1/02/2012 | Journal of Medical Imaging and Radiation Oncology |
| 3.04 | RADAR | Genitourinary | Wilcox C, Kautto A, Steigler A, Denham J. Androgen Deprivation Therapy for prostate cancer does not increase cardiovascular mortality in the long term. Oncol. 2012 Feb; 82(1):56-8. | A | 1/02/2012 | Oncology |
| 2.01 | - | Skin | Burmeister BH, Henderson MA, Ainslie J, Fisher R, Di Iulio J, Smithers BM, Hong A, Kerwin S, Scolyer RA, Curruthjers S, Coventry BJ, Babington S, Duprat J, Hoekstra HJ, Thompson. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Lancet Oncol 2012 Jun; 13(6):589-97. | A | 1/06/2012 | Lancet Oncology |
| 10.01 | BOLART | Genitourinary | Kron T, Pham D, Roxby P, Rolfo A, Foroudi F. Credentialing of radiotherapy centres for a clinical trial of adaptive radiotherapy for bladder cancer (TROG 10.01). Radiother Oncol, 2012 Jun; 103(3):293-98. | A | 1/06/2012 | Radiotherapy and Oncology |
| 2.02 | - | Head and Neck | Le QT, Fisher R, Oliner KS, Young RJ, Cao H, Kong C, Graves E, Hicks RJ, McArthur GA, Peters L, OSullivan B, Giacia A, Rischin D. Prognostic and predictive significance of plasma HGF and IL-8 in a phase III trial of chemoradiation with or without Tirapazamine in locoregionally advanced head and neck cancer. Clin Cancer Res. 2012 Jun; 18(6):1798-807. | A | 1/06/2012 | Clinical Cancer Research |
| 2.02 | - | Head and Neck | Lim AM, Young RJ, Collins M, Fox SB, McArthur GA, Corry J, Peters L, Rischin D, Solomon B. Correlation of Ataxia-Telangiectasia-Mutated gene loss with outcome in head and neck squamous cell carcinoma. Oral Oncol. 2012 Aug; 48(8):689-702. | A | 1/08/2012 | Oral Oncology |
| 4.01 | - | Symptom Management | Graham P, Plant N, Graham J, Browne L, Martin Borg M, Capp A, Delaney, Harvey J, Kenny L, Francis M, Zissiadis Y. Digital photography as source documentation of skin toxicity: An analysis from the Trans Tasman Radiation Oncology Group (TROG) 04.01 Post-Mastectomy Radiation Skin Care Trial. J Med Imag Radiat Oncol. 2012 Aug; 56(4):458-63. | A | 1/08/2012 | Journal of Medical Imaging and Radiation Oncology |
| 1.04 | - | Gastrointestinal | Ngan S, Burmeister B, Fisher R, Solomon M, Goldstein D, Joseph D, Ackland S, Schache D, McClure B, McLachlan S, McKendrick J, Leong T, Hartopeanu C, Zalcberg and Mackay J. Randomized trial of short course radiotherapy versus long course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer (TROG01.04). J Clin Oncol. 2012 Nov; 30(31):3827-33. | A | 1/11/2012 | Journal of Clinical Oncology |
| 3.04 | RADAR | Genitourinary | Denham JW, Wilcox C, Joseph D, Spry N, Lamb D, Tai K-H, Matthews J, Atkinson C, Turner S, Christie D, Gogna NK, Kenny L, Duchesne G, Delahunt B, McElduff P. Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial. Lancet Oncol. 2012 Dec; 13(12):1260-70. | A | 1/12/2012 | Lancet Oncology |
| 3.04 | RADAR | Genitourinary | Denham JW, Wilcox C, Lamb D, Spry N, Duchesne G, Atkinson C, Matthews J, Turner S, Kenny L, Tai K-H, Gogna NK, Ebert M, Delahunt B, McElduff P, Joseph D. Rectal and Urinary Dysfunction in the TROG 03.04 RADAR Trial for Locally Advanced Prostate Cancer. Radiother Oncol. 2012 Nov; 105(2):184-92. | A | 1/11/2012 | Radiotherapy and Oncology |
| 96.01 | - | Genitourinary | Steigler, Allison, James W. Denham, David S. Lamb, Nigel A. Spry, David Joseph, John Matthews, Chris Atkinson, Turner S, North J, Christie D, Tai K-H, Wynne C. Risk Stratification after Biochemical Failure following Curative Treatment of Locally Advanced Prostate Cancer: Data from the TROG 96.01 Trial. Prostate Cancer. 2012 Dec; 2012:814724. | A | 1/12/2012 | Prostate Cancer |
| 9.02 | CHISEL | Lung | Siva S, Shaw M, Chesson B, Gill S and Ball D. Analysis of the impact of chest wall constraints on eligibility for a randomized trial of stereotactic body radiotherapy of peripheral stage I non-small cell lung cancer. J Med Imag Radiat Oncol. 2012 Dec; 56(6):654-60. | A | 1/12/2012 | Journal of Medical Imaging and Radiation Oncology |
| 9.02 | CHISEL | Lung | Clements N, Kron T, Franich R, Dunn L, Roxby P, Aarons Y, Siva S, Chesson B, Duplan D, Ball D. The effect of irregular breathing patterns on internal target volumes in four-dimensional CT and cone-beam CT images in the context of stereotactic lung radiotherapy. Med Phys. 2013 Feb; 40(2):021904. | A | 1/02/2013 | Medical Physics |
| 99.05 | - | Lung | Ball D, Fisher R, Burmeister B, Poulsen M, Graham P, Penniment M, Vinod S, Krawitz H, Joseph D, Wheeler G, McClure B. The complex relationship between lung tumor volume and survival in patients with non-small cell lung cancer treated by definitive radiotherapy: a prospective, observational prognostic factor study of the Trans-Tasman Radiation Oncology Group (TROG 99.05). Radiother Oncol. 2013 Mar; 106(3):305-11. | A | 1/03/2013 | Radiotherapy and Oncology |
| 3.04 | RADAR | Genitourinary | Geraghty JP, Grogan G, Ebert MA. Automatic segmentation of male pelvic anatomy on computed tomography images: a comparison with multiple observers in the context of a multicentre clinical trial. Radiat Oncol. 2013 Apr; 8:106 | A | 1/04/2013 | Radiotherapy and Oncology |
| 2.02 | Head and Neck | Ohri N, Shen X, Dicker A, Doyle L, Harrison A, Showalter T. Radiotherapy Protocol Deviations and Clinical Oucomes: A Meta-Analysis of Cooperative Group Clinical Trials. J Natl Cancer Inst. 2013 Mar; 105(6):387-93. | A | 1/03/2013 | Journal of the National Cancer Institute | |
| 3.04 | RADAR | Genitourinary | Kearvell R, Haworth A, Ebert MA, Murray J, Hooton B, Richardson S, Joseph DJ, Lamb D, Spry NA, Duchesne G, Denham JW. Quality improvements in prostate radiotherapy: Outcomes and impacts of comprehensive quality assurance during the TROG 03.04 RADAR trial. J Med Imag Radiat Oncol. 2013 Apr; 57(2):24757. | A | 1/04/2013 | Journal of Medical Imaging and Radiation Oncology |
| 9.03 | MP3 | Skin | Finnigan R, Hruby G, Wratten C, Keller J, Tripcony L, Dickie G, Rischin D, Poulsen M. The impact of pre-radiation residual disease volume on time to locoregional failure in cutaneous merkel cell carcinoma A TROG substudy. Int J Radiat Oncol Biol Phys. 2013 May; 86(1):91-5. | A | 1/05/2013 | International Journal of Radiation Oncology Biology Physics |
| 4.01 | - | Symptom Management | Graham PH, Plant N, Browne L, Borg M, Capp A, Delaney G, Harvey J, Kenny L, Francis M, Zissiadis Y. A paired double blind randomised comparison of a moisturising durable barrier cream (MDBC) to 10% glycerine ("Sorbolene") cream in the prophylactic management of post-mastectomy irradiation skin care. Trans Tasman Radiation Oncology Group (TROG) 04.01. Int J Radiat Oncol Biol Phys. 2013 May; 86(1):45-50. | A | 1/05/2013 | International Journal of Radiation Oncology Biology Physics |
| 10.01 | BOLART | Genitourinary | Pham D, Roxby P, Kron T, Rolfo A, Foroudi F. Introduction of Online Adaptive Radiotherapy for Bladder Cancer through a Multicentre Clinical Trial (TROG 10.01): Lessons Learned. Jour Med Phys. 2013 Apr; 38(2):59-66. | A | 1/04/2013 | Journal of Medical Physics |
| 96.01 | - | Genitourinary | Denham JW, Steigler A, Tai K-H, Joseph D, Matthews J, Atkinson C, Spry NA, Turner S, North J, Christie C, Wynne C, Lamb DS. Paradoxical metastatic progression following 3 months of neo-adjuvant androgen suppression in the TROG 96.01 trial for men with locally advanced prostate cancer. Radiother Oncol. 2013 May; 107(2):123-28. | A | 1/05/2013 | Radiotherapy and Oncology |
| 8.01 | PROFIT | Genitourinary | Martin J, Frantzis J, Chung P, Langah I, Crain M, Cornes D, Plank A, Finch T, Jones M, Khoo E, Catton C. Prostate Radiotherapy Clinical Trial Quality Assurance: How Real Should Real Time Review Be? (A TROG-OCOG Intergroup Project). Radiother Oncol. 2013 Jun; 107(3):333-38. | B | 1/06/2013 | Radiotherapy and Oncology |
| 8.01 | PROFIT | Genitourinary | Healy B, Frantzis J, Murry R, Martin J, Plank A, Middleton M, Catton C, Kron T. Results from a multicentre prostate IMRT dosimetry intercomparison for an OCOG-TROG clinical trial. Med Phys. 2013 Jul; 40(7):071706. | B | 1/07/2013 | Medical Physics |
| TROG | - | NA | Christie D. Accrual to Trans-Tasman Radiation Oncology Group-sponsored trials 2010-2012. J Med Imag Radiat Oncol. 2013 Aug; 57(4):499-502. | NA | 1/08/2013 | Journal of Medical Imaging and Radiation Oncology |
| 99.05 | - | Lung | Ball D, Fisher R, McClure B. Response to Dahele and Senan. Radiother Oncol.12 October 2013;109 (1):180-181.(Refers to Max Dahele, Suresh Senan. What causes early mortality in patients with large tumors receiving radical chemo-radiotherapy for non-small cell lung cancer? In response to Ball et al. Radiother Oncol. 2013 Sep; 109: 178-82. | A | 1/09/2013 | Radiotherapy and Oncology |
| 10.01 | BOLART | Genitourinary | Foroudi F, Pham D, Bressel M, Tongs D, Rolfo A, styles C, Gill S, Kron T. The utility of e-Learning to support training for a multicentre bladder online adaptive radiotherapy trial (TROG 10.01-BOLART). Radiother Oncol. 2013 Oct; 109(1):165-69. | A | 1/10/2013 | Radiotherapy and Oncology |
| 10.02 | RAPID | Breast | Olivotto IA, Whelan TJ, Parpia S, Kim DH, Berrang T, Truong PT, Kong I, Cochrane B, Nichol A, Roy I, Germain I, Akra M, Reed M, Fyles A, Trotter T, Perera F, Beckham W, Levine MN, Julian JA. Interim Cosmetic and Toxicity Results From RAPID: A Randomized Trial of Accelerated Partial Breast Irradiation Using Three-Dimensional Conformal External Beam Radiation Therapy. J Clin Oncol. 2013 Nov; 31(32):4038-45. | B | 1/11/2013 | Journal of Clincal Oncology |
| 6.02 | APBI | Breast | Kron T, Willis D, Link E, Lehman M, Campbell G, OBrien P and Chua B. Can we predict plan quality for external beam partial breast irradiation: Results of a multicenter feasibility study (Trans Tasman Radiation Oncology Group Study 06.02). Int J Radiat Oncol Biol Phys. 2013 Nov 15; 87(4):817-824. | A | 1/11/2013 | International Journal of Radiation Oncology Biology Physics |
| 8.09 | RTN2 | Skin | Foote M. TROG 08.09 ANZMTG 01.09. An International Randomised Trial of Post-operative Radiation Therapy Following Wide Excision of Neurotropic Melanoma of the Head and Neck. J Dtsch Dermatol Ges. 2013; 11:57-58. | C | xx/xx/2013 | Journal of the German Society of Dermatology |
| TROG | - | NA | Grgoire V, Ang K, Budach W, Grau C, Hamoir M, Langendijk JA, Lee A, Le QT, Maingon P, Nutting C, OSullivan B, Porceddu S, Lengele B. Delineation of the neck node levels for head and neck tumors: A 2013 update. DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTOG, TROG consensus guidelines. Radiother Oncol. 2014 Jan; 110(1):172-81. | NA | 1/01/2014 | Radiotherapy and Oncology |
| 3.08 | - | Symptom Management | Chow E, van der Linden Y, Roos DE, Hartsell WF, Hoskin P, Wu Jackson S, Brundage M, Nabid A, Tissing-Tan C, Oei B, Babington S, Demas W, Wilson F, Meyer R, Chen B, Wong R. Single versus multiple fractions of repeat radiation for painful bone metastases: a randomised, controlled, non-inferiority trial. Lancet Oncol. 2014 Feb; 15(2):164-71. | B | 1/02/2014 | Lancet Oncology |
| 9.02 | CHISEL | Lung | Hardcastle N, Clements N, Chesson B, Aarons Y, Cramb J, Siva S, Wanigaratne DM, Ball D, Kron T. Results of patient specific quality assurance for patients undergoing stereotactic ablative radiotherapy for lung lesions. Australas Phys Eng Sci Med. 2014 Mar; 37(1):45-52. | A | 1/03/2014 | Australasian Physical and Enginerring Sciences in Medicine |
| 7.03 | DCIS | Head and Neck | Macann A, Fua T, Milross C, Porceddu S, Penniment M, Wratten C, Krawitz H, Poulsen M, Tang CI, Morton RP, Hay KD, Thomson V, Bell ML, King MT, Fraser-Browne CL, Hockey HP. Phase III trial of domiciliary humidification to mitigate acute mucosal toxicity during radiotherapy for head and neck cancer: First report of Trans Tasman Radiation Oncology Group (TROG) 07.03 RadioHUM study. Int J Radiat Oncol Biol Phys. 2014 Mar; 88(3):572-79 | A | 1/03/2014 | International Journal of Radiation Oncology Biology Physics |
| 8.03 | RAVES | Genitourinary | Pearse M, Fraser-Browne C, Davis ID, Duchesne GM, Fisher R, Frydenberg M, Haworth A, Jose C, Joseph DJ, Lim T, Matthews J, Millar J, Sidhom M, Spry N, Tang C, Turner S, Williams SG, Wiltshire K, Woo HH, Kneebone A. A phase III trial to investigate the timing of radiotherapy for prostate cancer with high-risk features: background and rationale of the RAVES trial (Radiotherapy Adjuvant Versus Early Salvage). BJU Int. 2014 Mar; 113(S2):7-12. | A | 1/03/2014 | BJU International |
| 3.04 | RADAR | Genitourinary | Chang D, Joseph DJ, Ebert MA, Galvao DA, Taaffe DR, Denham JW, et al. Effect of androgen deprivation therapy on muscle attenuation in men with prostate cancer. J Med Imag Radiat Oncol. 2014 Apr; 58(2):223-28. | A | 1/04/2014 | Journal of Medical Imaging and Radiation Oncology |
| 3.04 | RADAR | Genitourinary | Galvao DA, Spry N, Denham J, Taaffe DR, Cormie P, Joseph D, Lamb D, Chambers S, Newton R. A Multicentre Year-long Randomised Controlled Trial of Exercise Training Targeting Physical Functioning in Men with Prostate Cancer Previously Treated with Androgen Suppression and Radiation from TROG 03.04 RADAR. Eur Urol. 2014 May; 65(5):856-64. | A | 1/05/2014 | European Urology |
| 3.04 | RADAR | Genitourinary | Sharpley CF, Bitsika V, Denham JW. Factors associated with feelings of loss of masculinity in men with prostate cancer in the RADAR trial. Psycho-Oncology 2014 May; 23(5):524-30. | A | 1/05/2014 | Psycho Oncology |
| 10.01 | BOLART | Genitourinary | Foroudi F, Pham D, Rolfo A, Bressel M, Tang C, Tan A, Turner S, Hruby G, Williams S, Hayne D, Lehman M, Skala M, Jose C, Gogna K, Kron T. The outcome of a multi-centre feasibility study of Online Adaptive Radiotherapy for Muscle Invasive Bladder Cancer TROG 10.01 BOLART. Radiother Oncol. 2014 May; 111(2):316-20. | A | 1/05/2014 | Radiotherapy and Oncology |
| 8.03 | RAVES | Genitourinary | Sundaresan P, Turner S, Kneebone A, Pearse M, Fraser-Browne C, Woo HH. Do screening trial recruitment logs accurately reflect the eligibility criteria of a given clinical trial? Early Lessons from the 08.03 RAVES Trial. J Clin Oncol. 2014 Jun; 26(6):348-52. | A | 1/06/2014 | Journal of Clincal Oncology |
| - | - | NA | Christie D, Sharpley C. The successful contribution by the Trans-Tasman Radiation Oncology Group to intergroup radiation oncology trials (2010-2012) and a proposal for accrual definitions. Radiother Oncol. 2014 Jul; 112(1):153-54. | NA | 1/07/2014 | Radiotherapy and Oncology |
| 11. A | ANROTAT | NA | Carter H, Martin A, Schofield D, Duchesne G, Haworth A, Hornby C, Sidhom M, Jackson M. A decision model to estimate the cost-effectiveness of intensity modulated radiation therapy (IMRT) compared to three dimensional conformal radiation therapy (3DCRT) in patients receiving radiotherapy to the prostate bed. Radiother Oncol. 2014 Aug; 112(2):187-93. | A | 1/08/2014 | Radiotherapy and Oncology |
| 3.04 | RADAR | Genitourinary | Denham J, Joseph D, Lamb D, Spry N, Duchesne G, Matthews J, Atkinson C, Tai K, Christie D, Kenny L, Turner S, Gogna NK, Diamond T, Delahunt B, Oldmeadow C, Attia J, Steigler A. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial. Lancet Oncol. 2014 Sep; 15(10):1076-89. | A | 1/09/2014 | Lancet Oncology |
| 3.04 | RADAR | Genitourinary | Denham J, Nowitz M, Joseph D, Duschesne G, Spry N, Lamb D, Matthews J, Turner S, Atkinson C, Tai K-H, Gogna K, Kenny L, Diamond T, Smart R, Rowan D, Moscato P, Vimieiro R, Woodfield R, Lynch K, DEste C, McElduff P, Steigler A, Kautto A, Ball J. Impact of androgen suppression and zoledronic acid on bone mineral density and fractures in the TROG 03.04 RADAR trial for locally advanced prostate cancer. BJU Int. 2014 Sep; 114(3):344-53. | A | 1/09/2014 | BJU International |
| 3.04 | RADAR | Genitourinary | Elsner K, Francis K, Hruby G, & Roderick S. Quality improvement process to assess tattoo alignment, set-up accuracy and isocentre reproducibility in pelvic radiotherapy patients. J Med Radiat Sci. 2014 Dec; 61(4):246-52. | A | 1/12/2014 | Journal of Medical Radiation Sciences |
| 3.04 | RADAR | Genitourinary | Ebert M, Bulsara M, Haworth A, Kearvell R, Richardson S, Kennedy A, Spry N, Bydder S, Joseph D, Denham J. Technical quality assurance during the TROG 03.04 RADAR prostate radiotherapy trial: Are the results reflected in observed toxicity rates? J Med Imag Radiat Oncol. 2015 Feb; 59(1):99-108. | A | 1/02/2015 | Journal of Medical Imaging and Radiation Oncology |
| 3.04 | RADAR | Genitourinary | Ebert M, Foo K, Haworth A, Gulliford S, Kennedy A, Joseph D, Denham J. Gastrointestinal dose-histogram effects in the context of dose-volume-constrained prostate radiation therapy: analysis of data from the RADAR prostate radiation therapy trial. Int J Radiat Oncol Biol Phys. 2015 Mar; 91(3):595-603. | A | 1/03/2015 | International Journal of Radiation Oncology Biology Physics |
| 10.02 | RAPID | Breast | Peterson DJ, Truong PT, Parpia S, Olivotto IA, Berrang T, Kim D-H, Kong I, Germain I, Nichol A, Akra M, Roy I, Reed M, Fyles A, Trotter T, Perera F, Balkwill S, Lavertu S, Elliott E, Julian JA, Levine MN, Whelan TJ. Predictors of adverse cosmetic outcome in the RAPID trial: An exploratory analysis. Int J Radiat Oncol Biol Phys. 2015 Apr; 91(5):968-76. | B | 1/04/2015 | International Journal of Radiation Oncology Biology Physics |
| 8.05 | WBRT | Skin | Fogarty G, Hong A, Dolven-Jacobsen K, Reisse C, Burmeister B, Haydu L, Dhillon H, Steel V, Shivalingam B, Drummond K, Vardy J, Nowak A, Hruby G, Scolyer R, Mandel C, Thompson J. First interim analysis of a randomised trial of whole brain radiotherapy in melanoma brain metastases confirms high data quality. BMC Research Notes. 2015 May; 8(192). | C | 1/05/2015 | BMC Research notes |
| 11. A | ANROTAT | NA | Duchesne G, Grand M, Kron T, Haworth A, Corry J, Jackson M, Burmeister B. (2014). Trans Tasman Radiation Oncology Group: Development of the Assessment of New Radiation Oncology Technology and Treatments (ANROTAT) Framework. J Med Imag Radiat Oncol. 2015 Jun; 59(3):363-70. | A | 1/06/2015 | Journal of Medical Imaging and Radiation Oncology |
| 11. A | ANROTAT | NA | Brown E, Cray A, Haworth A, Chander S, Lin R, Subramanian B, Ng M. Dose planning objectives in anal canal cancer IMRT: the TROG ANROTAT experience. J Med Rad Sci. 2015 Jun; 62(2):99-107. | A | 1/06/2015 | Journal of Medical Radiation Sciences |
| 3.04 | RADAR | Genitourinary | Denham J, Steigler A , Joseph D, Lamb D, Spry NA, Duchesne G, Atkinson C, Matthews J, Turner S, Kenny L, Tai K-H, Gogna N, Gill S, Tan H, Kearvell R, Murray J, Ebert M, Haworth A, Kennedy A, Delahunt B, Oldmeadow C, Holliday E, Attia J. Radiation dose escalation or longer androgen suppression for locally advanced prostate cancer? Data from the TROG 03.04 RADAR trial. Radiother Oncol. 2015 Jun; 115(3):301-07. | A | 1/06/2015 | Radiotherapy and Oncology |
| 12.03 | EAT | Head and Neck | Britton B, McCarter K, Baker A, Wolfenden L, Wratten C, Bauer J, Beck A, McElduff P, Halpin S, Carter G. Eating As Treatment (EAT) study protocol: a stepped-wedge, randomised controlled trial of a health behaviour change intervention provided by dietitians to improve nutrition in patients with head and neck cancer undergoing radiotherapy. BMJ Open. 2015 Jul; 5(7):e008921. | C | 1/07/2015 | BMJ Open |
| 3.05 | MA.20 | Breast | Whelan T.J, Olivotto I, Parulekar W, Ackerman I, Chua B, Nabid A, Vallis K, White J, Rousseau P, Fortin A, Pierce L, Manchul L, Chafe S, Nolan M, Craighead P, Bowen J, McCready D, Pritchard K, Gelmon K, Murray Y, Chapman J, Chen B, Levine, M. Regional nodal irradiation in early-stage breast cancer. N Eng J Med. 2015 Jul; 373(4):307-16. | B | 1/07/2015 | New England Journal of Medicine |
| 3.04 | RADAR | Genitourinary | Yahya N, Ebert MA, Bulsara M, Haworth A, Kennedy A, Joseph DJ, Denham JW. Dosimetry, clinical factors and medication intake influencing urinary symptoms after prostate radiotherapy: An analysis of data from the RADAR prostate radiotherapy trial. Radiother Oncol. 2015 July; 116(1):112-8, | A | 1/07/2015 | Radiotherapy and Oncology |
| 2.01 | - | Skin | Henderson M, Burmeister B, Ainslie J, Fisher R, Di Iulio J, Smithers MB, Hong A, Shannon K, Scolyer RA, Carruthers S, Coventry B, Babington S, Duprat J, Hoekstra H, Thompson J. Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial. Lancet Oncol. 2015 Sep; 16(9):1049-60. | A | 1/09/2015 | Lancet Oncology |
| 3.04 | RADAR | Genitourinary | Delahunt B, Egevad L, Srigley JR, Steigler A, Murray JD, Atkinson C, Matthews J, Duchesne G, Spry NA, Christie D, Joseph D, Attia J, Denham JW. Validation of International Society of Urological Pathology (ISUP) grading for prostatic adenocarcinoma in thin core biopsies using TROG 03.04 RADAR trial clinical data. Pathology. 2015 Oct; 47(6):52025. | A | 1/10/2015 | Pathology |
| 12.03 | EAT | Head and Neck | Beck A, Baker A, Britton B, Wratten C, Bauer J, Wolfenden L, Carter G. Fidelity considerations in translational research: Eating As Treatment - a stepped wedge, randomised controlled trial of a dietitian delivered behaviour change counselling intervention for head and neck cancer patients undergoing radiotherapy. TRIALS. 2015 Oct; 16:465. | C | 1/10/2015 | Trials |
| 3.04 | RADAR | Genitourinary | Yahya N, Ebert M, Bulsara M, House M, Kennedy A, Joseph D, Denham J. Urinary symptoms following external beam radiotherapy of the prostate: Dose-symptom correlates with multiple-event and event-count models. Radiother Oncol. 2015 Nov; 117(2):277-82 | A | 1/11/2015 | Radiotherapy and Oncology |
| 8.03 | RAVES | Genitourinary | Trada Y, Kneebone A, Paneghel A, Pearse M, Sidhom M, Tang C, Wiltshire K, Haworth K, Fraser-Browne C, Martin J. Optimizing Radiation Therapy Quality Assurance in Clinical Trials: A TROG 08.03 RAVES Substudy. Int J Radiat Oncol Biol Phys. 2015 Dec; 93(5):1045-51. | A | 1/12/2015 | International Journal of Radiation Oncology Biology Physics |
| 3.06 | TOAD | Genitourinary | Duchesne G, Haworth A, Bone E, Carter H, Ebert M, Gagliardi F, Gibbs A, Hornby C, Martin A, Sidhom M, Wood M, Jackson M. Testing the Assessment of New Radiation Oncology Technologyand Treatments framework using the evaluation of post-prostatectomy radiotherapy techniques. J Med Imag Radiat Oncol. 2016 Feb; 60(1):129-37. | C | 1/02/2016 | Journal of Medical Imaging and Radiation Oncology |
| 1.04 | - | Gastrointestinal | McLachlan S, Fisher R, Zalcberg J, Solomon M, Burmeister B, Goldstein D, Leong T, Ackland S, McKendrick J, McClure B, Mackay J, Ngan S. The impact on health-related quality of life in the first 12 months: A randomised comparison of preoperative short-course radiation versus long-course chemoradiation for T3 rectal cancer (Trans-Tasman Radiation Oncology Group Trial 01.04). Eur J Cancer. 2016 Mar; 55:15-26. | A | 1/03/2016 | European Journal of Cancer |
| 8.03 | RAVES | Genitourinary | Tesson S, Sundaresan P, Ager B, Butow P, Kneebone A, Costa D, Woo H, Pearse M, Juraskova, Turner S. Knowledge, attitudes and decision-making preferences of men considering participation in the TROG RAVES Prostate Cancer Trial (TROG 08.03). Radiother Oncol.2016 Apr; 119(1):84-90. | A | 1/04/2016 | Radiotherapy and Oncology |
| 3.04 | RADAR | Genitourinary | Yahya N, Ebert MA, Bulsara M, House MJ, Kennedy A, Joseph DJ, Denham JW. Statistical-learning strategies generate only modestly performing predictive models for urinary symptoms following external beam radiotherapy of the prostate: A comparison of conventional and machine-learning methods. Med Phys. 2016 May; 43(5):2040 | A | 1/05/2016 | Medical Physics |
| 3.06 | TOAD | Genitourinary | Duchesne G, Woo H, Bassett J, Bowe S, D'Este C, Frydenberg M, King M, Ledwich L, Loblaw A, Malone S, Millar J, Milne R, Smith R, Spry N, Stockler M, Syme R, Tai K, Turner S. Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): A randomised, multicentre, non-blinded, phase 3 trial. Lancet Oncol. 2016 Jun; 17(6):727-37. | C | 1/06/2016 | Lancet Oncology |
| 8.04 | PORTEC-3 | Gynaecologic | de Boer S, Powell M, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger P, Ledermann J, Khaw P, Colombo A, Fyles A, Baron M, Kitchener H, Nijman H, Kruitwagen R, Nout R, Verhoeven-Adema K, Smit V, Putter H, Creutzberg C; PORTEC study group. Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2016 Jul; 17(8):1114-26. | C | 1/07/2016 | Lancet Oncology |
| 3.04 | RADAR | Genitourinary | Yahya N, Ebert MA, Bulsara M, Kennedy A, Joseph DJ, Denham JW. Independent external validation of predictive models for urinary dysfunction following external beam radiotherapy of the prostate: Issues in model development and reporting. Radiother Oncol. 2016 Aug; 120(2):339-45 | A | 1/08/2016 | Radiotherapy and Oncology |
| 13.01 | SAFRON II | Lung | Pham D, Hardcastle N, Foroudi F, Kron T, Bressel M, Hilder B, Chesson B, Oates R, Montgomery R, Ball D, Siva S. A Multidisciplinary Evaluation of a Web-based eLearning Training Programme for SAFRON II (TROG 13.01): A Multicentre Randomised Study of Stereotactic Radiotherapy for Lung Metastases. Clin Oncol. 2016 Sep; 28(9):e101-08. | A | 1/09/2016 | Clinical Oncology |
| 8.04 | PORTEC-3 | Gynaecologic | Jameson M, Mcnamara J, Bailey M, Metcalfe P, Holloway L, Foo K, Do V, Mileshkin L, Creutzberg, Khaw P. Results of the Australasian (Trans-Tasman Oncology Group) radiotherapy benchmarking exercise in preparation for participation in the PORTEC-3 trial. J Med Imag Radia Oncol. 2016 Sep; 60(4):554-59 | C | 1/09/2016 | Journal of Medical Imaging and Radiation Oncology |
| 3.04 | RADAR | Genitourinary | Sridharan S, Steigler A, Spry NA, Joseph D, Lamb DS, Matthew J, Atkinson C, Tai KH, Duchesne G, Christie D, Attia J, Holliday EG, Denham JW. Oligometastatic bone disease in prostate cancer patients treated on the TROG 03.04 RADAR trial. Radiother Oncol. 2016 Oct; 121(1):98-102. | A | 1/10/2016 | Radiotherapy and Oncology |
| 3.04 | RADAR | Genitourinary | Moulton CR, House MJ, Lye V, Tang CI, Krawiec M, Joseph DJ, Denham JW, Ebert MA. Prostate external beam radiotherapy combined with high-dose-rate brachytherapy: dose-volume parameters from deformably-registered plans correlate with late gastrointestinal complications. Radiat Oncol. 2016 Oct; 11(1):144 | A | 1/10/2016 | Radiation Oncology |
| 6.01 | LGG | CNS | Baumert B, Hegi M, Van Den Bent J, Von Deimling A, Gorlia T, Hoang-Xuan K, Brandes A, Kantor G, Taphoorn M, Ben Hassel M, Hartmann C, Ryan G, Capper D, Kros J, Kurscheild S, Wick W, Enting R, Reni M, Thiessen B, Dhermain F, Bromberg J, Feuvret L, Reijneveld J, Chinot O, Gijtenbeek J, Rossiter J, Dif N, Balana C, Barvo-Marques J, Clement P, Marosi C, Tzuk-Shina T, Nordal R, Rees J, Lacombe D, Mason W, Stupp R. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol. 2016 Nov; 17(11):1521-32. | B | 1/11/2016 | Lancet Oncology |
| 6.01 | LGG | CNS | Reijneveld J, Taphoorn M, Coens C, Bromber J, Mason W, Hoang-Xuan K, Ryan G, Beh Assel M, Enting R, Brandes A, Wick A, CHinot O, Reni M, Kantor G, Thiessen B, Klein M, Verger E, Borchers C, Hau P, Back M, Smits A, Golfinopoulous V, Gorlia T, Bottomley A, Stupp R, Baumert B. Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol. 2016 Nov; 17(11):1533-42. | B | 1/11/2016 | Lancet Oncology |
| 3.04 | RADAR | Genitourinary | Cicchetti A, Rancati T, Ebert M, Fiorino C, Palorini F, Kennedy A, Joseph DJ, Denham JW, Vavassori V, Fellin G, Avuzzi B, Stucchi C, Valdagni R. Modelling late stool frequency and rectal pain after radical radiotherapy in prostate cancer patients: Results from a large pooled population. Phys Med. 2016 Dec; 32(12):1690-7 | A | 1/12/2016 | Physics Medica |
| 11.01 | SUPREMO | Breast | Thomas J, Hanby A, Russell N, van Tienhoven G, Riddle K, Anderson N, Cameron D, Bartlett J, Bowman A, Piper T, Cunningham C, Canney P, Kunkler I. The BIG 2.04 MRC/EORTC SUPREMO Trial - Pathology quality assurance of a large phase 3 randomised international clinical trial of post mastectomy radiotherapy in intermediate-risk breast cancer. Breast Cancer Res Treat. 2017 Feb; 163(1):63-9. | B | 1/02/2017 | Breast Cancer Research and Treatment |
| 3.04 | RADAR | Genitourinary | Yahya N, Ebert MA, House MJ, Kennedy A, Matthews J, Joseph DJ, Denham JW. Modeling Urinary Dysfunction After External Beam Radiation Therapy of the Prostate Using Bladder Dose-Surface Maps: Evidence of Spatially Variable Response of the Bladder Surface. Int J Radiat Oncol Biol Phys. 2017 Feb; 97(2):420-6 | A | 1/02/2017 | International Journal of Radiation Oncology Biology Physics |
| 2.02 | - | Head and Neck | Ringash J, Fisher R, Peters L, Trotti A, O'Sullivan B, Corry J, Kenny L, Van Den Bogaert W, Wratten C, Rischin D. Effect of p16 Status on the Quality-of-Life Experience During Chemoradiation for Locally Advanced Oropharyngeal Cancer: A Substudy of Randomized Trial Trans-Tasman Radiation Oncology Group (TROG) 02.02 (HeadSTART). Int J Radiat Oncol Biol Phys. 2017 Mar; 97(4): 678-86 | A | 1/03/2017 | International Journal of Radiation Oncology Biology Physics |
| 8.02 | GBM | CNS | Perry J, Laperriere N, O'Callaghan C, Brandes A, Menten J, Phillips C, Fay m, Nishikava R, Carncross J, Roa W, Osoba D, Rossiter J, Sahgal A, Hirte H, Laigle-Donadey F, Franceschi E, Chinot O, Goldinopoulos V, Fariselli L, Wick A, Feuvret L, Back M, Tills M, Winch C, Baumert B, Wick W, Ding K, Mason W. Short-course radiation plus temozolomide in elderly patients with glioblastoma. New Engl J Med. 2017 Mar; 376(11):1027-37. | B | 1/03/2017 | New England Journal of Medicine |
| 8.05 | WBRT | Skin | Hong A; Hallock H; Valenzuela M; Lo S; Paton E; Ng D; Dhillon H; Jacobsen K; Reisse C; Fogarty G. Hippocampal avoidance whole brain radiation therapy is associated with preservation of hippocampal volume at six months: a case series. Neurooncol Open Access 2017 Mar; 1:1. | C | 1/03/2017 | Neuro Oncology Open Access |
| 3.04 | RADAR | Genitourinary | Bitska V, Sharpley CF, Bradford R, Steigler A, Denham JW. Measuring Personal and Functional Changes in Prostate Cancer Survivors: Development and validation of the FADE: Data from the TROG 03.04 RADAR trial. Psycho-Oncology. 2017 Apr; 26(4):553-55 | A | 1/04/2017 | Pyscho Oncology |
| 15.01 | SPARK | Genitourinary | Ngyuen D, O'Brien R, Kim J, Huang C, Booth J, Wilton L, Greer P, Legge K, Poulsen P, Martin J, Keall P. The First Clinical Implementation of a Real-Time Six Degree Of Freedom Tracking System For Intrafaction Prostate Motion During Radiation Therapy. Radiother and Oncol. 2017 Apr; 123(1):37-42 | C | 1/04/2017 | Radiotherapy and Oncology |
| 8.01 | PROFIT | Genitourinary | Catton C, Lukka H, Gu C, Martin J, Supiot S, Chung P, Bauman G, Bahary J, Ahmed S, Cheung P, Tai KH, Wu J, Parliament M, Tsakiridis T, Corbett T, Tang C, Days I, Warde P, Craig T, Julian J, Levine M. Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer. J Clin Oncol. 2017 Jun; 35(17):1884-90 | B | 1/06/2017 | Journal of Clinical Oncology |
| 7.04 | - | Head and Neck | Corry J, Bressel M, Fua T, Herschtal A, Solomon B, Porceddu SV, Wratten C, Rischin D. Prospective study of cetuximab, carboplatin and radiotherapy for patients with locally advanced head and neck squamous cell cancer (HNSCC) unfit for cisplatin. Int J Radiat Oncol Biol Phys. 2017 Jul; 98(4):948-54 | A | 1/07/2017 | International Journal of Radiation Oncology Biology Physics |
| 99.05 | - | Lung | Cox A, Akhurst T, Bressel M, MacManus M, Ball D. Survival and central photopenia detected by fluorine-18 fluoro-deoxy-glucose positron emission tomography (FDG-PET) in patients with locoregional non-small cell lung cancer treated with radiotherapy. Radiother and Oncol. 2017 Jul; 124(1):25-30 | A | 1/07/2017 | Radiotherapy and Oncology |
| 15.01 | SPARK | Genitourinary | Legge K, Greer P, Keall P, Booth J, Arumugam S, Moodie T, Nguyen D, Martin J, O'Connor D, Lehmann J. Technical Note: TROG 15.01 SPARK Trial Multi-Institutional Imaging Dose Measurement. J Appl Clin Med Phys. 2017 Jul; 18(5):358-63 | C | 1/07/2017 | Journal of Applied Clinical Medical Physics |
| 8.08 | WBRT | Gastrointestinal | Leong T, Smithers M, Haustermans K, Michael M, Gebski V, Miller D, Simes J, Zalcberg J, Boussioutas A, Findlay M, O'Connell R, Verghis J, Willis D, Kron T, Crain M, Murray W, Lordick F, Swallow C, Darling G, Wong R. TOPGEAR: A randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer. Interim results from an international, intergroup trial of the AGITG, TROG, EORTC and CCTG (formerly NCIC CTG). Ann Surg Oncol. 2017 Aug; 24(8): 2252-58 | C | 1/08/2017 | Annals of Surgical Oncology |
| 3.06 | TOAD | Genitourinary | Duchesne G, Woo H, King M, Bowe S, Stockler M, Ames A, et al. Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial. Lancet Oncol. 2017 Sep; 18(9):1192-1201 | C | 1/09/2017 | Lancet Oncology |
| 8.03 | RAVES | Genitourinary | Sundaresan P, Ager B, Turner S, Costa D, Kneebone A, Pearse M, et al. A randomised controlled trial evaluating the utility of a patient Decision Aid to improve clinical trial (RAVES 08.03) related decision-making. Radiother Oncol. 2017 Oct; 125(1): 124-29. | A | 1/10/2017 | Radiotherapy and Oncology |
| 3.04 | RADAR | Genitourinary | Sharpley, C.F., Bitsika, V., Christie, D.R.H., Bradford, R., Steigler, A., & Denham, J.W. Total Depression and Subtypes in Prostate Cancer Survivors 10 years after treatment. Eur J Cancer Care. 2017 Nov; 26(6):e12630 | A | 1/11/2017 | European Journal of Cancer Care |
| 7.03 | DCIS | Head and Neck | Macann A, Fauzi F, Simpson J, Sasso G, Krawitz H, Fraser-Browne C, Manitz J, Raith A. Humidification mitigates acute mucosal toxicity during radiotherapy when factoring volumetric parameters. Trans Tasman Radiation Oncology Group (TROG) RadioHUM 07.03 substudy. Oral Oncol. 2017 Dec; 75:75-80. | A | 1/12/2017 | Oral Oncology |
| TROG | - | Head and Neck | Delineation of the primary tumour Clinical Target Volumes (CTV-P) in laryngeal, hypopharyngeal, oropharyngeal and oral cavity squamous cell carcinoma: AIRO, CACA, DAHANCA, EORTC, GEORCC, GORTEC, HKNPCSG, HNCIG, IAG-KHT, LPRHHT, NCIC CTG, NCRI, NRG Oncology, PHNS, SBRT, SOMERA, SRO, SSHNO, TROG consensus guidelines. Radiother Oncol. 2018 Jan; 126(1):3-24. | NA | 1/01/2018 | Radiotherapy and Oncology |
| 3.01 | Gastrointestinal | Penniment M, De Ieso P, Harvey J, Stephens S, Au H, O'Callaghan C, Kneebone A, Ngan S, Ward I, Roy R, Smith J, Nijjar T, Biagi J, Mulroy L, Wong R; TROG 03.01/CCTG ES.2 group. Palliative chemoradiotherapy versus radiotherapy alone for dysphagia in advanced oesophageal cancer: a multicentre randomised controlled trial (TROG 03.01). Lancet Gastroenterol Hepatol. 2018 Feb; 3(2):114-24. | A | 1/02/2018 | Lancet Gastroenterolgy and heptalogy | |
| 3.04 | RADAR | Genitourinary | Marcello M, Ebert M, Haworth A, Steigler A, Kennedy A, Joseph D, Denham J. Association between treatment planning and delivery factors and disease progression in prostate cancer radiotherapy: results from the TROG 03.04 RADAR trial. Radioth Oncol. 2018 Feb; 126(2):249-56. | A | 1/02/2018 | Radiotherapy and Oncology |
| 9.03 | MP3 | Skin | Poulsen M, Macfarlane D, Veness M, Estall V, Hruby G, Kumar M, Pullar A, Tripcony L, Rischin D. Prospective analysis of the utility of 18-FDG PET in Merkel cell carcinoma of the skin: A Trans Tasman Radiation Oncology Group Study, TROG 09:03. J Med Imag Radiat Oncol. 2018 Feb; 62(3):412-9. | A | 1/02/2018 | Journal Of Medical Imaging And Radiation Oncology |
| 8.04 | PORTEC-3 | Gynaecologic | de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, et al. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2018 Feb; 19(3):295309. | C | 1/02/2018 | Lancet Oncology |
| 9.02 | CHISEL | Lung | Kron T, Chesson B, Hardcastle N, Crain M, Clements N, Burns M, Ball D. Credentialing of radiotherapy centres in Australasia for TROG 09.02 (Chisel) a Phase III clinical trial on stereotactic ablative body radiotherapy of early stage lung cancer. Br J Radiol. 2018 Mar; 91(1085):20170737. | A | 1/03/2018 | British Journal of Radiology |
| 3.04 | RADAR | Genitourinary | Marcello M, Ebert M, Haworth A, Steigler A, Kennedy A, Bulsara M, Kearvell R, Joseph D, Denham J. Association between measures of treatment quality and disease progression in prostate cancer radiotherapy: results from the TROG 03.04 RADAR trial. J Med Imag Radiat Oncol. 2018 Apr; 62(2):248-55. | A | 1/04/2018 | Journal Of Medical Imaging And Radiation Oncology |
| 15.01 | SPARK | Genitourinary | Keall P, Nguyen D, O'Brien R, Caillet V, Hewson E, Poulsen P, Bromley R, Bell L, Eade T, Kneebone A, Martin J, Booth J. The first clinical implementation of real-time image-guided adaptive radiotherapy using a standard linear accelerator. Radiother Oncol. 2018 Apr; 127(1):6-11. | C | 1/04/2018 | Radiotherapy and Oncology |
| 6.01 | LGG | CNS | Gao Y, Weenink B, van den Bent MJ, Erdem-Eraslan L, Kros JM, Sillevis Smitt P, Hoang-Xuan K, Brandes AA, Vos M, Dhermain F, Enting R, Ryan GF, Chinot O, Ben Hassel M, van Linde ME, Mason WP, Gijtenbeek JMM, Balana C, von Deimling A, Gorlia T, Stupp R, Hegi ME, Baumert BG, French PJ. Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC 22033-26033 clinical trial. Eur J Cancer. 2018 May; 94:168-78. | B | 1/05/2018 | European Journal of Cancer |
| 5.01 | POST | Skin | Porceddu S, Bressel M, Poulsen M, Stoneley A, Veness M, Kenny L, Wratten C, Corry J, Cooper S, Fogarty G, Collins M, Collins M, Macann A, Milross C, Penniment M, Liu H, King M, Panizza B, Rischin D. Postoperative Concurrent Chemoradiotherapy Versus Postoperative Radiotherapy in High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck: The Randomized Phase III TROG 05.01 Trial. J Clin Oncol. 2018 May; 36(13):1275-83. | A | 1/05/2018 | Journal of Clinical Oncology |
| 99.03 | - | Lymphoma | MacManus M, Fisher R, Roos D, O'Brien P, Macann A, Davis S, Tsang R, Christie D, McClure B, Joseph D, Jayamohan J, Seymour J. A Randomized Trial of Systemic Therapy after involved-field Radiotherapy in patients with Early Stage Follicular Lymphoma: TROG 99.03. J Clin Oncol. 2018 Oct; 36(29):2918-25. | A | 1/10/2018 | Journal of Clinical Oncology |
| 12.03 | EAT | Head & Neck | Britton B, Baker A, Wolfenden L, Wratten C, Bauer J, Beck A, McCarter K, Harrowfield J, Isenring E, Tang C, Oldmeadow C, Carter G. Eating As Treatment (EAT): a stepped-wedge, randomised controlled trial of a health behaviour change intervention provided by dietitians to improve nutrition in patients with head and neck cancer undergoing radiotherapy (TROG 12.03). Int J Radiat Oncol Biol Phys. 2019 Feb; 103(2):353-62. | C | 1/02/2019 | International Journal of Radiation Oncology Biology Physics |
| 3.04 | RADAR | Genitourinary | Denham J, Joseph D, Lamb D, Spry N, Duchesne G, Matthews J, Atkinson C, Tai K, Christie D, Kenny L, Turner S, Gogna K, Diamond T, Delahunt B, Oldmeadow C, Attia J, Steigler A. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial. Lancet Oncol. 2019 Feb; 20(2):267-81. | A | 1/02/2019 | Lancet Oncology |
| 9.02 | CHISEL | Lung | Ball D, Mai T, Vinod S, Babington S, Ruben J, Kron T, Chesson B, Herschtal A, Vaneski M, Rezo A, Elder C, Skala M, Wirth A, Wheeler G, Lim A, Shaw M, Schofield P, Irving L, Le H. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial. Lancet Oncol. 2019 Apr; 20(4):494-503. | A | 1/04/2019 | Lancet Oncology |
| 3.03 | Lymphoma | Wirth A, Prince H, Roos D, Gibson J, O'Brien P, Zannino D, Khodr B, Stone J, Davis S, Hertzberg M. A Prospective, Multicenter Study of Involved-Field Radiation Therapy With Autologous Stem Cell Transplantation for Patients With Hodgkin Lymphoma and Aggressive Non-Hodgkin Lymphoma (ALLG HDNHL04/TROG 03.03). Int J Radiat Oncol Biol Phys. 2019 Apr; 103(5):1158-1166 | C | 1/04/2019 | International Journal of Radiation Oncology Biology Physics | |
| 8.03 | RAVES | Prostate | Cloak K, Jameson M, Paneghel A, Wiltshire K, Kneebone A, Pearse M, Sidhom M, Tang C, Fraser-Browne C, Holloway L, Haworth A. Contour variation is a primary source of error when delivering post prostatectomy radiotherapy: Results of the Trans Tasman Radiation Oncology Group 08.03 Radiotherapy Adjuvant Versus Early Salvage (RAVES) benchmarking exercise. J Med Imaging Radiat Oncol. 2019 Jun; 63(3):390-8. | A | 1/06/2019 | Journal of Medical Imaging and Radiation Oncology |
| 15.01 | SPARK | Prostate | Wolf J, Nicholls J, Hunter P, Nguyen D, Keall P, Martin J. Dosimetric impact of intrafraction rotations in stereotactic prostate radiotherapy: A subset analysis of the TROG 15.01 SPARK trial. Radiother Oncol. 2019 Jul; 136:143-7. | C | 1/07/2019 | Radiotherapy and Oncology |
| 8.04 | PORTEC-3 | Gynaecologic | de Boer S, Powell M, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger P, Ledermann J, Khaw P, Colombo A, Fyles A, Baron M, Kitchener H, Nijman H, Kruitwagen R, Nout R, Verhoeven-Adema K, Smit V, Putter H, Creutzberg C; PORTEC study group. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. Lancet Oncol. 2019 Jul; 20(9):1273-85. | C | 1/07/2019 | Lancet Oncology |
| 15.01 | SPARK | Prostate | Hewson E, Nguyen D, O'Brien R, Kim J, Montanaro T, Moodie T, Greer P, Hardcastle N, Eade T, Kneebone A, Hruby G, Hayden A, Turner S, Siva S, Tai K, Hunter P, Sams J, Poulsen P, Booth J, Martin J, Keall P. The accuracy and precision of the KIM motion monitoring system used in the multi-institutional TROG 15.01 Stereotactic Prostate Ablative Radiotherapy with KIM (SPARK) trial. Med Phys. 2019 Nov; 46(11): 4725-37. | C | 1/11/2019 | Medical Physics |
| 8.05 | WBRT | Skin | Hong A, Fogarty G, Dolven-Jacobsen K, Burmeister B, Lo S, Haydu L, Vardy J, Nowak A, Dhillon H, Ahmed T, Shivalingam B, Long G, Menxies A, Hruby G, Drummond K, Mandel C, Middleton M, Reisse C, Paton E, Steel V, Williams N, Scolyer R, Morton R, Thompson J. Adjuvant Whole-Brain Radiation Therapy Compared With Observation After Local Treatment of Melanoma Brain Metastases: A Multicenter, Randomized Phase III Trial. J Clin Oncol. 2019 Nov; 37(33): 3132-41. | C | 1/11/2019 | Journal of Clinical Oncology |
| 11.02 | SCORAD III | Symptom Management | Hoskin P.J, Hopkins K., Misra V, Holt T, Mcmenemin R, Dubois D, Mckinna F, Foran B, Madhavan K, Macgregor C, Bates A, O'rourke N, Lester J.F, Sevitt T, Roos D, Dixit S, Brown G, Arnott S, Thomas S.S, Forsyth S, Beare S, Reczko K, Hackshaw A, Lopes A. Effect of Single-Fraction vs Multifraction Radiotherapy on Ambulatory Status among Patients with Spinal Canal Compression from Metastatic Cancer: The SCORAD Randomized Clinical Trial. JAMA. 2019 Dec; 322(21):2084-94. | B | 1/12/2019 | Journal of the American Medical Association |
| 10.02 | RAPID | Breast | Whelan TJ, Julian JA, Berrang TS, Kim DH, Germain I, Nichol AM, Akra M, Lavertu S, Germain F, Fyles A, Trotter T, Perera FE, Balkwill S, Chafe S, McGowan T, Muanza T, Beckham WA, Chua BH, Gu CS, Levine MN, Olivotto IA; RAPID Trial Investigators. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. Lancet. 2019 Dec 14;394(10215):2165-72. | B | 1/12/2019 | Lancet |
| 7.01 | DCIS | Breast | Olivotto I, Link E, Phillips C, Whelan T, Bryant G, Kunkler I, Westenberg A, Purohit K, Ahern V, Graham P, Akra M, McArdle O, Ludbrook J, Harvey J, Maduro J, Kirkove C, Gruber G, Martin J, Campbell I, Delaney G, Chua BH; BIG 03-07/TROG 07.01 trial investigators. International comparison of cosmetic outcomes of breast conserving surgery and radiation therapy for women with ductal carcinoma in situ of the breast. Radiother Oncol. 2020 Jan; 142:180-5. | A | 1/01/2020 | Radiotherapy and Oncology |
| NA | - | NA | Hardcastle N, Bignell F, Nelms B, Siva S, Kneebone A, Lao L, Cook O, Harris M, Shakeshaft J. The challenge of planning vertebral body SBRT: Optimising target volume coverage. Med Dosim. 2020 Apr; 45(3):302-7. | NA | 1/04/2020 | Medical Dosimetry |
| 16.01 | NIVORAD | Lung | Hardcastle N, Kron T, Cook O, Lehmann J, Mitchell P, Siva S. Credentialing of vertebral stereotactic ablative body radiotherapy in a multi-centre trial. Phys Med. 2020 Apr; 72:16-21 | C | 1/04/2020 | European Journal of Medical Physics |
| NA | - | NA | McDowell L, Goode S, Sundaresan P. Adapting to a global pandemic through live virtual delivery of a cancer collaborative trial group conference: The TROG 2020 experience. J Med Imaging Radiat Oncol. 2020 Jun; 64(3):414-21. | NA | 1/06/2020 | Journal of Medical Imaging and Radiation Oncology |
| 7.01 | DCIS | Breast | King MT, Link EK, Whelan TJ, Olivotto IA, Kunkler I, Westenberg AH, Gruber G, Schofield P, Chua BH; BIG 3-07/TROG 07.01 trial investigators. Quality of life after breast conserving therapy for non-low risk ductal carcinoma in situ: two-year results of a randomised controlled trial (BIG 3-07/TROG 07.01). Lancet Oncol. 2020 May; 21(5):685?698. | A | 1/05/2020 | Lancet Oncology |
| 18.04 | MASTERPLAN | Pancreas | Oar A, Lee M, Le H, Hruby G, Dalfsen R, Pryor D, Lee D, Chu J, Holloway L, Briggs A, Barbour A, Chander S, Ng S, Samra J, Shakeshaft J, Goldstein D, Nguyen N, Goodman K, Chang DT, Kneebone A. Australasian Gastrointestinal Trials Group (AGITG) and Trans-Tasman Radiation Oncology Group (TROG) Guidelines for Pancreatic Stereotactic Body Radiotherapy (SBRT). Pract Radiat Oncol. 2020 Jun; 10(3):e136-46. | C | 1/06/2020 | Practical Radiation Oncology |
| 3.04 | RADAR | Prostate | Panettieri V, Rancati T, Onjukka E, Ebert MA, Joseph DJ, Denham JW, Steigler A, Millar JL. External Validation of a Predictive Model of Urethral Strictures for Prostate Patients Treated With HDR Brachytherapy Boost. Front Oncol. 2020 Jun;10:910. | A | 1/06/2020 | Frontiers in Oncology |
| 15.01 | SPARK | Prostate | Keall P, Nguyen D, O'Brien R, Hewson E, Ball H, Poulsen P, Booth J, Greer P, Hunter P, Wilton L, Bromley R, Kipritidis J, Eade T, Kneebone A, Hruby G, Moodie T, Hayden A, Turner S, Arumugam S, Sidhom M, Hardcastle N, Siva S, Tai K, Gebski V, Martin J. Real-Time Image Guided Ablative Prostate Cancer Radiation Therapy: Results From the TROG 15.01 SPARK Trial. Int J Radiat Oncol Biol Phys. 2020 Jul; 107(3):530-8. | C | 1/07/2020 | International Journal of Radiation Oncology Biology Physics |
| 17.11 | C-POST | Head and Neck | Porceddu SV, Daniels C, Yom SS, Liu H, Waldron J, Gregoire V, Moore A, Veness M, Yao M, Johansen J, Mehanna H, Rischin D, Le QT. Head and Neck Cancer International Group (HNCIG) Consensus Guidelines for the Delivery of Postoperative Radiation Therapy in Complex Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN). Int J Radiat Oncol Biol Phys. 2020 Jul; 107(4):641-651. | C | 1/07/2020 | International Journal of Radiation Oncology Biology Physics |
| 3.04 | RADAR | Prostate | Marcello M, Denham JW, Kennedy A, Haworth A, Steigler A, Greer PB, Holloway LC, Dowling JA, Jameson MG, Roach D, Joseph DJ, Gulliford SL, Dearnaley DP, Sydes MR, Hall E, Ebert MA. Relationships between rectal and perirectal doses and rectal bleeding or tenesmus in pooled voxel-wise analysis of 3 randomised phase 3 trials. Radioth Oncol. 2020 Sep; 150: 281-92. | A | 1/09/2020 | Radiotherapy and Oncology |
| 8.03 | RAVES | Prostate | Kneebone A, Fraser-Browne C, Duchesne G, Fisher R, Frydenberg M, Herschtal A, Williams S, Delprado W, Haworth A, Joseph D, Martin J, Matthews J, Millar J, Sidhom M, Spry N, Tang C, Turner S, Wiltshire K, Woo H, Davis I, Lim T, Pearse M. A Phase III Multi-Centre Randomised Trial comparing adjuvant versus early salvage Radiotherapy following a Radical Prostatectomy: Results of the TROG 08.03 and ANZUP "RAVES" Trial. Lancet Oncol. 2020 Oct; 21:1331-40. | A | 1/10/2020 | Lancet Oncology |
| 15.01 | SPARK | Prostate | Hewson E, Nguyen D, O'Brien R, Poulsen P, Booth J, Greer P, Eade T, Kneebone A, Hruby G, Moodie T, Hayden A, Turner S, Hardcastle N, Siva S, Tai K, Keall P. Is multileaf collimator tracking or gating a better intrafraction motion adaptation strategy? An analysis of the TROG 15.01 Stereotactic Prostate Ablative Radiotherapy with KIM (SPARK) trial. Radiother Oncol. 2020 Oct; 151: P234-41. | C | 1/10/2020 | Radiotherapy and Oncology |
| 8.03 | RAVES | Prostate | Vale C, Fisher D, Kneebone A, Parker C, Pearse M, Richaud P, Sargos P, Sydes M, Brawley C, Brihoum M, Brown C, Chabaud S, Cook A, Forcat S, Fraser-Browne C, Latorzeff I, Parmar M, Tierney J, for the ARTISITC Meta-analysis Group. Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data. Lancet. 2020 Oct; 396(10260):P1422-31. | A | 1/10/2020 | The Lancet |
| 12.01 | HPV OROPHARYNX | Head and Neck | Young R, Solomon B, Corry J, Angel C, Kenny L, Porceddu S, Wratten C, Macann A, Jackson J, Herschtal A, Rischin D. Validation of local p16 testing for determination of human papilloma virus status eligibility on a low risk oropharyngeal cancer trial A Trans-Tasman Radiation Oncology Group study. Oral Oncol. 2020 Nov; 110:104988. | A | 1/11/2020 | Oral Oncology |
| 9.01 | PROARCT | Gastrointestinal | Ng SP, Chu J, Chander S, Bressel M, McKendrick J, Wong R, Steel M, Murray WK, Leong T, Heriot A, Michael M, Ngan SY. Results of phase II trial of intensified neoadjuvant treatment with interdigitating radiotherapy and chemotherapy with oxaliplatin, 5-fluorouracil and folinic acid in patients with locally advanced rectal cancer (PROARCT trial). Radiother Oncol. 2021 Feb; 155:27-32. | A | 1/02/2021 | Radiotherapy and Oncology |
| 8.04 | PORTEC-3 | Gynaecologic | Post CCB, de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger N(P)B, Ledermann JA, Khaw P, D'Amico R, Fyles A, Baron MH, Kitchener HC, Nijman HW, Lutgens LCHW, Brooks S, Jrgenliemk-Schulz IM, Feeney A, Goss G, Fossati R, Ghatage P, Leary A, Do V, Lissoni AA, McCormack M, Nout RA, Verhoeven-Adema KW, Smit VTHBM, Putter H, Creutzberg CL, Long-term toxicity and health-related quality of life after adjuvant chemoradiotherapy or radiotherapy alone for high-risk endometrial cancer in the randomised PORTEC-3 trial. Int J Radiat Oncol Biol Phys. 2021 Mar; 109(4):975-86. | C | 1/03/2021 | International Journal of Radiation Oncology Biology Physics |
| 11.03 | P_LUNG GP | Lung | Lehman M, Bernard A, See A, King M, Michael M. A Randomised Phase III Trial of Palliative Radiotherapy (PRT) versus Concurrent Chemotherapy and PRT (C-PRT) in Patients with Good Performance Status, Locally Advanced or Metastatic NSCLC with symptoms due to intrathoracic disease who are not suitable for radical Chemo-radiotherapy: Results of the Trans-Tasman Radiation Oncology Group (TROG) 11.03 Trial. Pract Radiat Oncol. In Press | A | In Press | Practical Radiation Oncology |
| 3.04 | RADAR | Prostate | Marcello M, Denham JW, Kennedy A, Haworth A, Steigler A, Greer PB, Holloway LC, Dowling JA, Jameson MG, Roach D, Joseph DJ, Gulliford SL, Dearnaley DP, Sydes MR, Hall E, Ebert MA. Reduced dose posterior to prostate predicts for increased treatment failure in pooled voxel-wise analysis of 3 randomised phase 3 trials. Int J Radiat Oncol Biol Phys. In press | A | In Press | International Journal of Radiation Oncology Biology Physics |
For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.
Latest News
Keep up to date with TROG news, subscribe to our community newsletter.
ABN: 45 132 672 292